Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Peters, S. Pujol, J.-. Dafni, U. Dómine, M. Popat, S. Reck, M. Andrade, J. Becker, A. Moro-Sibilot, D. Curioni-Fontecedro, A. Molinier, O. Nackaerts, K. Insa Mollá, A. Gervais, R. López Vivanco, G. Madelaine, J. Mazieres, J. Faehling, M. Griesinger, F. Majem, M. González Larriba, J.L. Provencio Pulla, M. Vervita, K. Roschitzki-Voser, H. Ruepp, B. Mitchell, P. Stahel, R.A. Le Pechoux, C. De Ruysscher, D. Stahel, R. Hiltbrunner, A. Pardo-Contreras, M. Gasca-Ruchti, A. Giacomelli, N. Kammler, R. Marti, N. Pfister, R. Piguet, A.C. Roux, S. Troesch, S. Schneider, M. Schweri, R. Zigomo, I. Tsourti, Z. Zygoura, P. Tsouprou, S. Kassapian, M. Vervita, K. Dimopoulou, G. Andriakopoulou, C. Morin, F. Amour, E. Mariaule, G. Archirel, N. Fernandez, M. Pereira, E. Benito, L. Lopez, K. Hernández, A. Chinchen, S. Jurkovic, H. Livingstone, A. Mitchell, J. Walker, M. Mitchell, P. Ng, S. Steer, C. Briscoe, K. Saqib, A. Abdi, E. Houghton, B. O’Byrne, K. Chittajallu, B.R. Hughes, B.G. Black, A. Nackaerts, K. Werner, H. Gervais, R. Zalcman, G. Vaylet, F. Merle, P. Monnet, I. Moro-Sibilot, D. Molinier, O. Girard, N. Souquet, P.-. Barlesi, F. Debieuvre, D. Senellart, H. Poudenx, M. Dixmier, A. Pouessel, D. Cadranel, J. Lena, H. Quoix, E. Friard, S. Audigier-Valette, C. Mazieres, J. Pichon, E. Faehling, M. Kokowski, K. Kirchen, H. Griesinger, F. Tufman, A. De-Colle, C. de Langen, J. González Larriba, J.L. Insa, A. Majem, M. Massutí, B. Pulla, M.P. Aix, S.P. Villanueva, N. Vivanco, G.L. Andrade, J. Curioni-Fontecedro, A. Franks, K. Califano, R. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of oncology, Vol.33 (1), pp. 67-79.

Popat, S. Baas, P. Faivre-Finn, C. Girard, N. Nicholson, A.G. Nowak, A.K. Opitz, I. Scherpereel, A. Reck, M. (2022). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of oncology, Vol.33 (2), pp. 129-142.

Coleman, N. Harbery, A. Heuss, S. Vivanco, I. Popat, S. (2022). Targeting un-MET needs in advanced non-small cell lung cancer. Lung cancer, Vol.164, pp. 56-68.

Navani, N. Baldwin, D.R. Edwards, J.G. Evison, M. McDonald, F. Nicholson, A.G. Fenemore, J. Sage, E.K. Popat, S. (2022). Lung Cancer in the United Kingdom. Journal of thoracic oncology, Vol.17 (2), pp. 186-193.

Peters, S. Scherpereel, A. Cornelissen, R. Oulkhouir, Y. Greillier, L. Kaplan, M.A. Talbot, T. Monnet, I. Hiret, S. Baas, P. Nowak, A.K. Fujimoto, N. Tsao, A.S. Mansfield, A.S. Popat, S. Zhang, X. Hu, N. Balli, D. Spires, T. Zalcman, G. (2022). First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of oncology : official journal of the european society for medical oncology, .  show abstract

Coker, E.A. Stewart, A. Ozer, B. Minchom, A.R. Pickard, L. Ruddle, R. Carreira, S. Popat, S. O'Brien, M.E. Raynaud, F.I. de Bono, J.S. Al-Lazikani, B. Banerji, U. (2022). Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes. Molecular cancer therapeutics, .  show abstract

Fendler, A. Shepherd, S.T. Au, L. Wilkinson, K.A. Wu, M. Schmitt, A.M. Tippu, Z. Farag, S. Rogiers, A. Harvey, R. Carlyle, E. Edmonds, K. Del Rosario, L. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Korteweg, J. Foley, T. Barber, T. Emslie-Henry, A. Caulfield-Lynch, N. Byrne, F. Shum, B. Gerard, C.L. Deng, D. Kjaer, S. Song, O.-. Queval, C. Kavanagh, C. Wall, E.C. Carr, E.J. Namjou, S. Caidan, S. Gavrielides, M. MacRae, J.I. Kelly, G. Peat, K. Kelly, D. Murra, A. Kelly, K. O’Flaherty, M. Shea, R.L. Gardner, G. Murray, D. Popat, S. Yousaf, N. Jhanji, S. Van As, N. Young, K. Furness, A.J. Pickering, L. Beale, R. Swanton, C. Gandhi, S. Gamblin, S. Bauer, D.L. Kassiotis, G. Howell, M. Nicholson, E. Walker, S. Wilkinson, R.J. Larkin, J. Turajlic, S. (2022). Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer cell, Vol.40 (4), pp. 438-438.

O'Sullivan, H. d'Arienzo, P.D. Yousaf, N. Cui, W. Popat, S. (2022). Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib. European journal of cancer, Vol.166, pp. 38-40.

Passaro, A. Leighl, N. Blackhall, F. Popat, S. Kerr, K. Ahn, M.J. Arcila, M.E. Arrieta, O. Planchard, D. de Marinis, F. Dingemans, A.M. Dziadziuszko, R. Faivre-Finn, C. Feldman, J. Felip, E. Curigliano, G. Herbst, R. Jänne, P.A. John, T. Mitsudomi, T. Mok, T. Normanno, N. Paz-Ares, L. Ramalingam, S. Sequist, L. Vansteenkiste, J. Wistuba, I.I. Wolf, J. Wu, Y.L. Yang, S.R. Yang, J.C. Yatabe, Y. Pentheroudakis, G. Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of oncology, Vol.33 (5), pp. 466-487.

Scherpereel, A. Antonia, S. Bautista, Y. Grossi, F. Kowalski, D. Zalcman, G. Nowak, A.K. Fujimoto, N. Peters, S. Tsao, A.S. Mansfield, A.S. Popat, S. Sun, X. Lawrance, R. Zhang, X. Daumont, M.J. Bennett, B. McKenna, M. Baas, P. (2022). First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung cancer, Vol.167, pp. 8-16.

Reckamp, K.L. Lin, H.M. Cranmer, H. Wu, Y. Zhang, P. Walton, L.J. Kay, S. Cichewicz, A. Neupane, B. Fahrbach, K. Popat, S. Camidge, D.R. (2022). Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future oncology, Vol.18 (20), pp. 2499-2510.  show abstract

Zauderer, M.G. Szlosarek, P.W. Le Moulec, S. Popat, S. Taylor, P. Planchard, D. Scherpereel, A. Koczywas, M. Forster, M. Cameron, R.B. Peikert, T. Argon, E.K. Michaud, N.R. Szanto, A. Yang, J. Chen, Y. Kansra, V. Agarwal, S. Fennell, D.A. (2022). EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. The lancet oncology, Vol.23 (6), pp. 758-767.

Luigi Banna, G. Addeo, A. Zygoura, P. Tsourti, Z. Popat, S. Curioni-Fontecedro, A. Nadal, E. Shah, R. Pope, A. Fisher, P. Spicer, J. Roy, A. Gilligan, D. Gautschi, O. Janthur, W.-. López-Castro, R. Roschitzki-Voser, H. Dafni, U. Peters, S. Stahel, R.A. (2022). A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. Lung cancer, Vol.169, pp. 77-83.

Cui, W. Milner-Watts, C. O'Sullivan, H. Lyons, H. Minchom, A. Bhosle, J. Davidson, M. Yousaf, N. Scott, S. Faull, I. Kushnir, M. Nagy, R. O'Brien, M. Popat, S. (2022). Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. European journal of cancer, Vol.171, pp. 44-54.

Popat, S. Liu, S.V. Scheuer, N. Hsu, G.G. Lockhart, A. Ramagopalan, S.V. Griesinger, F. Subbiah, V. (2022). Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature communications, Vol.13 (1).  show abstract

Cui, W. Milner-Watts, C. McVeigh, T.P. Minchom, A. Bholse, J. Davidson, M. Yousaf, N. MacMahon, S. Mugalaasi, H. Gunapala, R. Lee, R. George, A. Popat, S. O'Brien, M. (2022). A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung cancer (amsterdam, netherlands), Vol.165, pp. 34-42.  show abstract

Whisenant, J.G. Baena, J. Cortellini, A. Huang, L.-. Lo Russo, G. Porcu, L. Wong, S.K. Bestvina, C.M. Hellmann, M.D. Roca, E. Rizvi, H. Monnet, I. Boudjemaa, A. Rogado, J. Pasello, G. Leighl, N.B. Arrieta, O. Aujayeb, A. Batra, U. Azzam, A.Y. Unk, M. Azab, M.A. Zhumagaliyeva, A.N. Gomez-Martin, C. Blaquier, J.B. Geraedts, E. Mountzios, G. Serrano-Montero, G. Reinmuth, N. Coate, L. Marmarelis, M. Presley, C.J. Hirsch, F.R. Garrido, P. Khan, H. Baggi, A. Mascaux, C. Halmos, B. Ceresoli, G.L. Fidler, M.J. Scotti, V. Métivier, A.-. Falchero, L. Felip, E. Genova, C. Mazieres, J. Tapan, U. Brahmer, J. Bria, E. Puri, S. Popat, S. Reckamp, K.L. Morgillo, F. Nadal, E. Mazzoni, F. Agustoni, F. Bar, J. Grosso, F. Avrillon, V. Patel, J.D. Gomes, F. Ibrahim, E. Trama, A. Bettini, A.C. Barlesi, F. Dingemans, A.-. Wakelee, H. Peters, S. Horn, L. Garassino, M.C. Torri, V. TERAVOLT study group, (2022). A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. Journal of thoracic oncology : official publication of the international association for the study of lung cancer, .  show abstract

Griesinger, F. Cox, O. Sammon, C. Ramagopalan, S.V. Popat, S. (2022). Health technology assessments and real-world evidence: tell us what you want, what you really, really want. , Vol.11 (5), pp. 297-299.

Popat, S. Navani, N. Kerr, K.M. Smit, E.F. Batchelor, T.J. Van Schil, P. Senan, S. McDonald, F. (2021). Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. The oncologist, Vol.26 (2), pp. e306-e315.  show abstract

Baas, P. Scherpereel, A. Nowak, A.K. Fujimoto, N. Peters, S. Tsao, A.S. Mansfield, A.S. Popat, S. Jahan, T. Antonia, S. Oulkhouir, Y. Bautista, Y. Cornelissen, R. Greillier, L. Grossi, F. Kowalski, D. Rodríguez-Cid, J. Aanur, P. Oukessou, A. Baudelet, C. Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The lancet, Vol.397 (10272), pp. 375-386.

Chang, W. Zhang, Y.Z. Wolf, J.L. Hermelijn, S.M. Schnater, J.M. Thüsen, J.H. Rice, A. Lantuejoul, S. Mastroianni, B. Farver, C. Black, F. Popat, S. Nicholson, A.G. (2021). Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. Histopathology, Vol.78 (3), pp. 434-444.

Yang, J.C. Reckamp, K.L. Kim, Y.-. Novello, S. Smit, E.F. Lee, J.-. Su, W.-. Akerley, W.L. Blakely, C.M. Groen, H.J. Bazhenova, L. Carcereny Costa, E. Chiari, R. Hsia, T.-. Golsorkhi, T. Despain, D. Shih, D. Popat, S. Wakelee, H. (2021). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. Jto clinical and research reports, Vol.2 (2), pp. 100114-100114.

Joshi, K. Muhith, A. Obeid, M. Milner-Watts, C. Yousaf, N. Popat, S. Davidson, M. Bhosle, J. O’Brien, M. Minchom, A. (2021). Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung cancer, Vol.156, pp. 147-150.

Cui, W. Popat, S. (2021). Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. Drugs, Vol.81 (9), pp. 971-984.

Adizie, J.B. Tweedie, J. Khakwani, A. Peach, E. Hubbard, R. Wood, N. Gosney, J.R. Harden, S.V. Beckett, P. Popat, S. Navani, N. (2021). Biomarker Testing for People With Advanced Lung Cancer in England. Jto clinical and research reports, Vol.2 (6), pp. 100176-100176.

Manickavasagar, T. Yuan, W. Carreira, S. Gurel, B. Miranda, S. Ferreira, A. Crespo, M. Riisnaes, R. Baker, C. O'Brien, M. Bhosle, J. Popat, S. Banerji, U. Lopez, J. de Bono, J. Minchom, A. (2021). HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung cancer management, , pp. ?-? (12).

Nicholson, A.G. Moreira, A.L. Mino-Kenudson, M. Popat, S. (2021). Grading in Lung Adenocarcinoma: Another New Normal. Journal of thoracic oncology, Vol.16 (10), pp. 1601-1604.

Popat, S. Sharma, B. MacMahon, S. Nicholson, A.G. Sharma, R.K. Schuster, K. Lang Lazdunski, L. Fennell, D. (2021). Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment. Jco precision oncology, (5), pp. 39-43.

Cui, W. Popat, S. (2021). Pleural mesothelioma (PM) – The status of systemic therapy. Cancer treatment reviews, Vol.100, pp. 102265-102265.

Nastase, A. Mandal, A. Lu, S.K. Anbunathan, H. Morris-Rosendahl, D. Zhang, Y.Z. Sun, X.-. Gennatas, S. Rintoul, R.C. Edwards, M. Bowman, A. Chernova, T. Benepal, T. Lim, E. Taylor, A.N. Nicholson, A.G. Popat, S. Willis, A.E. MacFarlane, M. Lathrop, M. Bowcock, A.M. Moffatt, M.F. Cookson, W.O. (2021). Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Scientific reports, Vol.11 (1).  show abstract

Willis-Owen, S.A. Domingo-Sabugo, C. Starren, E. Liang, L. Freidin, M.B. Arseneault, M. Zhang, Y. Lu, S.K. Popat, S. Lim, E. Nicholson, A.G. Riazalhosseini, Y. Lathrop, M. Cookson, W.O. Moffatt, M.F. (2021). Y disruption, autosomal hypomethylation and poor male lung cancer survival. Scientific reports, Vol.11 (1), pp. 12453-?.  show abstract

Camidge, D.R. Kim, H.R. Ahn, M.-. Yang, J.C. Han, J.-. Hochmair, M.J. Lee, K.H. Delmonte, A. Garcia Campelo, M.R. Kim, D.-. Griesinger, F. Felip, E. Califano, R. Spira, A.I. Gettinger, S.N. Tiseo, M. Lin, H.M. Liu, Y. Vranceanu, F. Niu, H. Zhang, P. Popat, S. (2021). Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of thoracic oncology : official publication of the international association for the study of lung cancer, .  show abstract

Popat, S. Jung, H.A. Lee, S.Y. Hochmair, M.J. Lee, S.H. Escriu, C. Lee, M.K. Migliorino, M.R. Lee, Y.C. Girard, N. Daoud, H. Märten, A. Miura, S. (2021). Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung cancer (amsterdam, netherlands), Vol.162, pp. 9-15.  show abstract

Lindsay, C.R. Shaw, E.C. Moore, D.A. Rassl, D. Jamal-Hanjani, M. Steele, N. Naheed, S. Dick, C. Taylor, F. Adderley, H. Black, F. Summers, Y. Evans, M. Rice, A. Fabre, A. Wallace, W.A. Nicholson, S. Haragan, A. Taniere, P. Nicholson, A.G. Laing, G. Cave, J. Forster, M.D. Blackhall, F. Gosney, J. Popat, S. Kerr, K.M. (2021). Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. British journal of cancer, Vol.125 (9), pp. 1210-1216.  show abstract

Ou, S.-. Gadgeel, S.M. Barlesi, F. Yang, J.C. De Petris, L. Kim, D.-. Govindan, R. Dingemans, A.-. Crino, L. Léna, H. Popat, S. Ahn, J.S. Dansin, E. Mitry, E. Müller, B. Bordogna, W. Balas, B. Morcos, P.N. Shaw, A.T. (2020). Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung cancer, Vol.139, pp. 22-27.

Camidge, D.R. Kim, H.R. Ahn, M.-. Yang, J.C. Han, J.-. Hochmair, M.J. Lee, K.H. Delmonte, A. García Campelo, M.R. Kim, D.-. Griesinger, F. Felip, E. Califano, R. Spira, A. Gettinger, S.N. Tiseo, M. Lin, H.M. Gupta, N. Hanley, M.J. Ni, Q. Zhang, P. Popat, S. (2020). Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of clinical oncology, Vol.38 (31), pp. 3592-3603.  show abstract

Felip, E. Ardizzoni, A. Ciuleanu, T. Cobo, M. Laktionov, K. Szilasi, M. Califano, R. Carcereny, E. Griffiths, R. Paz-Ares, L. Duchnowska, R. Garcia, M.A. Isla, D. Jassem, J. Appel, W. Milanowski, J. Van Meerbeeck, J.P. Wolf, J. Li, A. Acevedo, A. Popat, S. (2020). CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European journal of cancer, Vol.127, pp. 160-172.

Zhang, Y.Z. Brambilla, C. Molyneaux, P.L. Rice, A. Robertus, J.L. Jordan, S. Lim, E. Lang-Lazdunski, L. Begum, S. Dusmet, M. Anikin, V. Beddow, E. Finch, J. Asadi, N. Popat, S. Cookson, W.O. Moffatt, M.F. Nicholson, A.G. (2020). Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. American journal of surgical pathology, Vol.44 (3), pp. 347-356.

Minchom, A. Yuan, W. Crespo, M. Gurel, B. Figueiredo, I. Wotherspoon, A. Miranda, S. Riisnaes, R. Ferreira, A. Bertan, C. Pereira, R. Clarke, M. Baker, C. Ang, J.E. Fotiadis, N. Tunariu, N. Carreira, S. Popat, S. O'Brien, M. Banerji, U. de Bono, J. Lopez, J. (2020). Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. Journal for immunotherapy of cancer, Vol.8 (1).  show abstract

Yang, J.C. Schuler, M. Popat, S. Miura, S. Heeke, S. Park, K. Märten, A. Kim, E.S. (2020). Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of thoracic oncology, Vol.15 (5), pp. 803-815.

Remon, J. Passiglia, F. Ahn, M.-. Barlesi, F. Forde, P.M. Garon, E.B. Gettinger, S. Goldberg, S.B. Herbst, R.S. Horn, L. Kubota, K. Lu, S. Mezquita, L. Paz-Ares, L. Popat, S. Schalper, K.A. Skoulidis, F. Reck, M. Adjei, A.A. Scagliotti, G.V. (2020). Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of thoracic oncology, Vol.15 (6), pp. 914-947.

Popat, S. Grohé, C. Corral, J. Reck, M. Novello, S. Gottfried, M. Radonjic, D. Kaiser, R. (2020). Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung cancer, Vol.144, pp. 76-84.

Evison, M. Edwards, J. McDonald, F. Popat, S. (2020). Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. Clinical oncology, Vol.32 (8), pp. 527-536.

Coleman, N. Yousaf, N. Arkenau, H.-. Welsh, L. Popat, S. (2020). Lorlatinib Salvages Central Nervous System–Only Relapse on Entrectinib in ROS1-Positive NSCLC. Journal of thoracic oncology, Vol.15 (8), pp. e142-e144.

Lim, E. Darlison, L. Edwards, J. Elliott, D. Fennell, D.A. Popat, S. Rintoul, R.C. Waller, D. Ali, C. Bille, A. Fuller, L. Ionescu, A. Keni, M. Kirk, A. Koh, P. Lau, K. Mansy, T. Maskell, N.A. Milton, R. Muthukumar, D. Pope, T. Roy, A. Shah, R. Shamash, J. Tasigiannopoulos, Z. Taylor, P. Treece, S. Ashton, K. Harris, R. Joyce, K. Warnes, B. Mills, N. Stokes, E.A. Rogers, C. (2020). Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. Bmj open, Vol.10 (9), pp. e038892-e038892.  show abstract

Middleton, G. Brock, K. Savage, J. Mant, R. Summers, Y. Connibear, J. Shah, R. Ottensmeier, C. Shaw, P. Lee, S.-. Popat, S. Barrie, C. Barone, G. Billingham, L. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The lancet respiratory medicine, Vol.8 (9), pp. 895-904.

Zhang, Y.Z. Brambilla, C. Molyneaux, P.L. Rice, A. Robertus, J.L. Jordan, S. Lim, E. Lang‐Lazdunski, L. Begum, S. Dusmet, M. Anikin, V. Beddow, E. Finch, J. Asadi, N. Popat, S. Quesne, J.L. Husain, A.N. Cookson, W.O. Moffatt, M.F. Nicholson, A.G. (2020). Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2‐tier nuclear grade. Histopathology, Vol.77 (3), pp. 423-436.

Bartlett, E.C. Kemp, S.V. Ridge, C.A. Desai, S.R. Mirsadraee, S. Morjaria, J.B. Shah, P.L. Popat, S. Nicholson, A.G. Rice, A.J. Jordan, S. Begum, S. Mani, A. Derbyshire, J. Morris, K. Chen, M. Peacock, C. Addis, J. Martins, M. Kaye, S.B. Padley, S.P. Devaraj, A. McDonald, F. Robertus, J.L. Lim, E. Barnett, J. Finch, J. Dalal, P. Yousaf, N. Jamali, A. Ivashniova, N. Phillips, C. Newsom-Davies, T. Lee, R. Vaghani, P. Whiteside, S. Vaughan-Smith, S. (2020). Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation. Lung cancer, Vol.148, pp. 12-19.

Tokaca, N. Cui, W. Hazell, S. Nicholson, A.G. Van As, N. Popat, S. (2020). Squamous Non–Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of TMPRSS2-ERG Translocation With SOX2 Amplification. Jco oncology practice, Vol.16 (10), pp. 695-697.

Coleman, N. Woolf, D. Welsh, L. McDonald, F. MacMahon, S. Yousaf, N. Popat, S. (2020). EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. Journal of thoracic oncology, Vol.15 (10), pp. e162-e165.

Popat, S. Curioni-Fontecedro, A. Dafni, U. Shah, R. O'Brien, M. Pope, A. Fisher, P. Spicer, J. Roy, A. Gilligan, D. Gautschi, O. Nadal, E. Janthur, W.D. López Castro, R. García Campelo, R. Rusakiewicz, S. Letovanec, I. Polydoropoulou, V. Roschitzki-Voser, H. Ruepp, B. Gasca-Ruchti, A. Peters, S. Stahel, R.A. (2020). A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of oncology, Vol.31 (12), pp. 1734-1745.

Cui, W. Cotter, C. Sreter, K.B. Heelan, K. Creamer, D. Basu, T.N. Handy, J. Walsh, S. Popat, S. (2020). Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non–Small-Cell Lung Cancer. Jco oncology practice, Vol.16 (12), pp. 842-844.

Middleton, G. Fletcher, P. Popat, S. Savage, J. Summers, Y. Greystoke, A. Gilligan, D. Cave, J. O’Rourke, N. Brewster, A. Toy, E. Spicer, J. Jain, P. Dangoor, A. Mackean, M. Forster, M. Farley, A. Wherton, D. Mehmi, M. Sharpe, R. Mills, T.C. Cerone, M.A. Yap, T.A. Watkins, T.B. Lim, E. Swanton, C. Billingham, L. (2020). Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, Vol.585 (7826), pp. E21-E21.

Middleton, G. Fletcher, P. Popat, S. Savage, J. Summers, Y. Greystoke, A. Gilligan, D. Cave, J. O’Rourke, N. Brewster, A. Toy, E. Spicer, J. Jain, P. Dangoor, A. Mackean, M. Forster, M. Farley, A. Wherton, D. Mehmi, M. Sharpe, R. Mills, T.C. Cerone, M.A. Yap, T.A. Watkins, T.B. Lim, E. Swanton, C. Billingham, L. (2020). The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, Vol.583 (7818), pp. 807-812.

Lim, K.H. Popat, S. (2020). Highlights in lung cancer in 2019. Esmo open, Vol.5 (1), pp. e000676-e000676.

Reck, M. Kerr, K.M. Grohé, C. Manegold, C. Pavlakis, N. Paz-Ares, L. Huber, R.M. Popat, S. Thatcher, N. Park, K. Hilberg, F. Barrueco, J. Kaiser, R. (2019). Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future oncology (london, england), Vol.15 (12), pp. 1363-1383.  show abstract

Tsao, A. Nakano, T. Nowak, A.K. Popat, S. Scagliotti, G.V. Heymach, J. (2019). Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in oncology, Vol.46 (2), pp. 145-154.

Califano, R. Hochmair, M.J. Gridelli, C. Delmonte, A. Garcia Campelo, M.R. Bearz, A. Griesinger, F. Morabito, A. Felip, E. Ghosh, S. Tiseo, M. Haney, J. Kerstein, D. Popat, S. Camidge, D.R. (2019). Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of oncology, Vol.30, pp. ii48-ii48.

Planchard, D. Popat, S. Kerr, K. Novello, S. Smit, E.F. Faivre-Finn, C. Mok, T.S. Reck, M. Van Schil, P.E. Hellmann, M.D. Peters, S. (2019). Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of oncology, Vol.30 (5), pp. 863-870.

Scagliotti, G.V. Gaafar, R. Nowak, A.K. Nakano, T. van Meerbeeck, J. Popat, S. Vogelzang, N.J. Grosso, F. Aboelhassan, R. Jakopovic, M. Ceresoli, G.L. Taylor, P. Orlandi, F. Fennell, D.A. Novello, S. Scherpereel, A. Kuribayashi, K. Cedres, S. Sørensen, J.B. Pavlakis, N. Reck, M. Velema, D. von Wangenheim, U. Kim, M. Barrueco, J. Tsao, A.S. (2019). Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. The lancet respiratory medicine, Vol.7 (7), pp. 569-580.

Mazieres, J. Drilon, A. Lusque, A. Mhanna, L. Cortot, A.B. Mezquita, L. Thai, A.A. Mascaux, C. Couraud, S. Veillon, R. Van den Heuvel, M. Neal, J. Peled, N. Früh, M. Ng, T.L. Gounant, V. Popat, S. Diebold, J. Sabari, J. Zhu, V.W. Rothschild, S.I. Bironzo, P. Martinez-Marti, A. Curioni-Fontecedro, A. Rosell, R. Lattuca-Truc, M. Wiesweg, M. Besse, B. Solomon, B. Barlesi, F. Schouten, R.D. Wakelee, H. Camidge, D.R. Zalcman, G. Novello, S. Ou, S.I. Milia, J. Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of oncology : official journal of the european society for medical oncology, Vol.30 (8), pp. 1321-1328.  show abstract

Coleman, N. Wotherspoon, A. Yousaf, N. Popat, S. (2019). Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung cancer, Vol.134, pp. 117-120.

Popat, S. (2019). Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep’s Clothing. Journal of thoracic oncology, Vol.14 (10), pp. 1689-1691.

Popat, S. (2019). Hyperprogression with immunotherapy: Is it real?. Cancer, Vol.125 (8), pp. 1218-1220.

Tokaca, N. Barth, S. O'Brien, M. Bhosle, J. Fotiadis, N. Wotherspoon, A. Thompson, L. Popat, S. (2018). Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. Journal of thoracic oncology : official publication of the international association for the study of lung cancer, Vol.13 (1), pp. 63-72.  show abstract

Melosky, B. Popat, S. Gandara, D.R. (2018). An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clinical lung cancer, Vol.19 (1), pp. 42-50.  show abstract

Felip, E. Hirsh, V. Popat, S. Cobo, M. Fülöp, A. Dayen, C. Trigo, J.M. Gregg, R. Waller, C.F. Soria, J.-. Goss, G.D. Gordon, J. Wang, B. Palmer, M. Ehrnrooth, E. Gadgeel, S.M. (2018). Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical lung cancer, Vol.19 (1), pp. 74-83.e11.  show abstract

Califano, R. Lal, R. Lewanski, C. Nicolson, M.C. Ottensmeier, C.H. Popat, S. Hodgson, M. Postmus, P.E. (2018). Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future oncology, Vol.14 (23), pp. 2415-2431.  show abstract

Curioni, A. Felip, E. Dafni, U. Molina, M.-. Gautschi, O. Peters, S. Massutí, B. Palmero, R. Ponce, S. Carcereny, E. Früh, M. Pless, M. Popat, S. Cuffe, S. Karachaliou, N. Kammler, R. Kassapian, M. Roschitzki-Voser, H. Stahel, R.A. Rosell, R. (2018). Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. Annals of oncology, Vol.29, pp. viii513-viii513.

Planchard, D. Popat, S. Kerr, K. Novello, S. Smit, E.F. Faivre-Finn, C. Mok, T.S. Reck, M. Van Schil, P.E. Hellmann, M.D. Peters, S. ESMO Guidelines Committee. Electronic address: [email protected], (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the european society for medical oncology, Vol.29 Suppl 4, pp. iv192-iv237.

Camidge, D.R. Kim, H.R. Ahn, M.-. Yang, J.C. Han, J.-. Lee, J.-. Hochmair, M.J. Li, J.Y. Chang, G.-. Lee, K.H. Gridelli, C. Delmonte, A. Garcia Campelo, R. Kim, D.-. Bearz, A. Griesinger, F. Morabito, A. Felip, E. Califano, R. Ghosh, S. Spira, A. Gettinger, S.N. Tiseo, M. Gupta, N. Haney, J. Kerstein, D. Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. The new england journal of medicine, Vol.379 (21), pp. 2027-2039.  show abstract

Popat, S. (2018). Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer. New england journal of medicine, Vol.378 (2), pp. 192-193.

Lindsay, C.R. Shaw, E.C. Blackhall, F. Blyth, K.G. Brenton, J.D. Chaturvedi, A. Clarke, N. Dick, C. Evans, T.R. Hall, G. Hanby, A.M. Harrison, D.J. Johnston, S.R. Mason, M.D. Morton, D. Newton-Bishop, J. Nicholson, A.G. Oien, K.A. Popat, S. Rassl, D. Sharpe, R. Taniere, P. Walker, I. Wallace, W.A. West, N.P. Butler, R. Gonzalez de Castro, D. Griffiths, M. Johnson, P.W. Rehal, P. Butler, S. Smith, M. Doak, R. Tanska, A. Halford, G. James, L. Kotara, C. Masson, G. Clokie, S. Bell, J. Macdonald, F. Griffiths, M. De Castro, D.G. Thompson, L. Mair, D. Lillis, S. Wren, D. Hollifield, R. Dover, K. Maurya, M. Brooks, D. Gomez, B. Grady, L. Jones, T. Hooper, C. Webster, D. Travis, J. Ogwuru, S. Gazdova, J. Collins, D. Chapman, E. Leavey, L. Proszek, P. Hulkki, S. Collins, V.P. Ibrahim, A. Brown, K. Burge, J. Burnett, K. Devonshire, G. Moseley, E. Haynes, B. Hodgkin, C. Jimenez-linan, M. Jones, L. Kenyon, G. Mahler-araujo, B. Payne, K. Piper, J. Rassl, D. Richardson, S. Rytina, E. Warren, A. Coker, L. Godsall, G. Arends, M. O’Neill, A. Rintoul, K. Goymer, D. Taylor, J. Matthews, C. Bhayani, H. Osalador, T. Niwaz, Z. Higgins, A. Bamsey, O. Salter, J. Renouf, L. Noel-Storr, G. Roberts, H. Gierejko, K. Knapman, P. Wotherspoon, A. Stamp, G. Attygailye, A. Hazell, S. Osin, P. Nerurkar, A. Francis, S. Runde, M. Arch, J. Chitnis, X. Siu, B. Townsend, D. Hennelly, L. Taylor, N. Johnson, B. Banerjee, S. Pyle, L. Hamill, M. Gyertson, J. George, A. Patel, K. Pearce, K. Edmonds, K. Sarker, S. Eeles, R. Bancroft, L. Taylor, N. Thomas, S. Kano, Y. Rowland, L. Brooks, K. Popat, S. O’brien, M. Bhosle, J. Priest, K. Ayite, B. Severn, J. Beedham, H. Lucas, N. Tye, K. Lorentzos, A. Webb, J. Kerr, S. Corestav, L. Bottero, D. Jell, L. Thomas, J. Marriott, C. Rajah, N. Cole, A. Ly, D. Taniere, P. O’sullivan, B. Swift, C. Hughes, F. Neil, D. Hanby, A. Banks, R. Ajayi, D. Barclay, A. Bishop, J.N. Beirne, D. Bernard, A. Berry, M. Bentley, J. Bishop, T. Chambers, A. Clarke, J. Crossley, A. Gahir, N. Gibson, D. Good, R. Grosios, K. Hall, G. Harnden, P. Hasler, K. Hindmarch, D. Jackson, S. Johnstone, C. Jones, A.-. Lambert, G. Lane, S. Mcnicholas, N. Millican-Slater, R. Moriaty, C. Newsham, A. O’connell, K. Ripley, L. Sebag-Montefiore, D. Simpson, M. Speirs, V. Sugden, J. Tate, L. Tidswell, E. Twelves, C. Walker, C. Waterhouse, B. Waugh, M. White, L. Wright, E. Rogan, J. Ashton, G. Abbey, C. Greenhalgh, M. Nonaka, D. Shing, E. Gibbard, C. Burton, G. Fawkes, N. Marsden, A. Waddington, R. Harrison, P. Moghadam, S. Murray, K. Brown, S. Mitchinson, C. Booton, R. Shah, R. Blackhall, F. Clarke, N. Harrison, D. Oniscu, A. Wallace, W. Rae, F. Marshall, C. Mcleod, L. Charles, M. Sutherland, S.J. Dawson, C. Mitchell, P. Maclellan, A. Muir, S. Johnstone, L. O’connor, J. Johnstone, S. Mcpherson, J. Hair, J. Pignatelli, M. Armstrong, R. Oien, K. Evans, J. Burgoyne, M. Blessing, K. Duthie, F. Moyes, C. Mallon, E. Millan, D. Roberts, F. Seywright, M. Fraser, S. Dick, C. Ford, I. Kean, S. Flood, M. Grant, D. Mcdonald, C. Moffat, T. Mclelland, H. Kyle, A. Cameron, G. Wright, M. Kenny, S. Mcauslan, K. Jones, A. Fitzsimons, T. Graham, F. Bell, A. Duffy, P. Fisher, A. Smith, A. Shannon, E. Woods, B. Hutchison, C. Booth, A. Duffy, L. Mcculloch, G. Sadiq, H. Deakin, S. Haywood, S. Mason, M. Chester, J. Parry-jones, A. Macarthur, A. Williams, S. Griffiths, D. Morgan, F. Bailey, H. (2018). Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. Esmo open, Vol.3 (6), pp. e000408-e000408.

Minchom, A. Thavasu, P. Ahmad, Z. Stewart, A. Georgiou, A. O'Brien, M.E. Popat, S. Bhosle, J. Yap, T.A. de Bono, J. Banerji, U. (2017). A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. Plos one, Vol.12 (10), pp. e0186106-?.  show abstract

Yap, T.A. Macklin-Doherty, A. Popat, S. (2017). Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. European journal of cancer (oxford, england : 1990), Vol.70, pp. 12-21.  show abstract

Yap, T.A. Popat, S. (2017). Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. Journal of thoracic oncology : official publication of the international association for the study of lung cancer, Vol.12 (1), pp. 12-14.

Juan, O. Yousaf, N. Popat, S. (2017). First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is…. Clinical oncology (royal college of radiologists (great britain)), Vol.29 (1), pp. e1-e4.

Juan, O. Popat, S. (2017). Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Lung cancer (amsterdam, netherlands), Vol.104, pp. 131-133.

Juan, O. Popat, S. (2017). Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic advances in medical oncology, Vol.9 (3), pp. 201-216.  show abstract

Papadatos-Pastos, D. Roda, D. De Miguel Luken, M.J. Petruckevitch, A. Jalil, A. Capelan, M. Michalarea, V. Lima, J. Diamantis, N. Bhosle, J. Molife, L.R. Banerji, U. de Bono, J.S. Popat, S. O'Brien, M.E. Yap, T.A. (2017). Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. European journal of cancer (oxford, england : 1990), Vol.75, pp. 56-62.  show abstract

Dolly, S.O. Collins, D.C. Sundar, R. Popat, S. Yap, T.A. (2017). Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, Vol.77 (8), pp. 813-827.  show abstract

Popat, S. (2017). Do Statins Improve Survival in Small-Cell Lung Cancer?. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (14), pp. 1497-1498.

Rosell, R. Dafni, U. Felip, E. Curioni-Fontecedro, A. Gautschi, O. Peters, S. Massutí, B. Palmero, R. Aix, S.P. Carcereny, E. Früh, M. Pless, M. Popat, S. Kotsakis, A. Cuffe, S. Bidoli, P. Favaretto, A. Froesch, P. Reguart, N. Puente, J. Coate, L. Barlesi, F. Rauch, D. Thomas, M. Camps, C. Gómez-Codina, J. Majem, M. Porta, R. Shah, R. Hanrahan, E. Kammler, R. Ruepp, B. Rabaglio, M. Kassapian, M. Karachaliou, N. Tam, R. Shames, D.S. Molina-Vila, M.A. Stahel, R.A. BELIEF collaborative group, (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet. respiratory medicine, Vol.5 (5), pp. 435-444.  show abstract

Gautschi, O. Milia, J. Filleron, T. Wolf, J. Carbone, D.P. Owen, D. Camidge, R. Narayanan, V. Doebele, R.C. Besse, B. Remon-Masip, J. Janne, P.A. Awad, M.M. Peled, N. Byoung, C.-. Karp, D.D. Van Den Heuvel, M. Wakelee, H.A. Neal, J.W. Mok, T.S. Yang, J.C. Ou, S.-. Pall, G. Froesch, P. Zalcman, G. Gandara, D.R. Riess, J.W. Velcheti, V. Zeidler, K. Diebold, J. Früh, M. Michels, S. Monnet, I. Popat, S. Rosell, R. Karachaliou, N. Rothschild, S.I. Shih, J.-. Warth, A. Muley, T. Cabillic, F. Mazières, J. Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (13), pp. 1403-1410.  show abstract

Popat, S. Mellemgaard, A. Reck, M. Hastedt, C. Griebsch, I. (2017). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future oncology (london, england), Vol.13 (13), pp. 1159-1171.  show abstract

Yap, T.A. Aerts, J.G. Popat, S. Fennell, D.A. (2017). Novel insights into mesothelioma biology and implications for therapy. Nature reviews. cancer, Vol.17 (8), pp. 475-488.  show abstract

Nimako, K. Ayite, B. Priest, K. Severn, J. Fries, H.M. Gunapala, R. Bhosle, J. Popat, S. O'Brien, M. (2017). A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic. European journal of cancer care, Vol.26 (4).  show abstract

Capelan, M. Roda, D. Geuna, E. Rihawi, K. Bodla, S. Kaye, S.B. Bhosle, J. Banerji, U. O'Brien, M. de Bono, J.S. Popat, S. Yap, T.A. (2017). Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung cancer (amsterdam, netherlands), Vol.111, pp. 6-11.  show abstract

Yousaf, N. Popat, S. (2017). Endocrine manifestations of malignancy. Medicine, Vol.45 (9), pp. 547-550.

Tokaca, N. Wotherspoon, A. Nicholson, A.G. Fotiadis, N. Thompson, L. Popat, S. (2017). Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung cancer (amsterdam, netherlands), Vol.111, pp. 65-68.  show abstract

Califano, R. Greystoke, A. Lal, R. Thompson, J. Popat, S. (2017). Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. Lung cancer (amsterdam, netherlands), Vol.111, pp. 51-58.  show abstract

Scagliotti, G.V. Gaafar, R. Nowak, A.K. Reck, M. Tsao, A.S. van Meerbeeck, J. Vogelzang, N.J. Nakano, T. von Wangenheim, U. Velema, D. Morsli, N. Popat, S. (2017). LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clinical lung cancer, Vol.18 (5), pp. 589-593.  show abstract

Yang, J.C. Ou, S.-. De Petris, L. Gadgeel, S. Gandhi, L. Kim, D.-. Barlesi, F. Govindan, R. Dingemans, A.-. Crino, L. Lena, H. Popat, S. Ahn, J.S. Dansin, E. Golding, S. Bordogna, W. Balas, B. Morcos, P.N. Zeaiter, A. Shaw, A.T. (2017). Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the international association for the study of lung cancer, Vol.12 (10), pp. 1552-1560.  show abstract

Grosso, F. Steele, N. Novello, S. Nowak, A.K. Popat, S. Greillier, L. John, T. Leighl, N.B. Reck, M. Taylor, P. Planchard, D. Sørensen, J.B. Socinski, M.A. von Wangenheim, U. Loembé, A.B. Barrueco, J. Morsli, N. Scagliotti, G. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (31), pp. 3591-3600.  show abstract

Juan, O. Popat, S. (2017). Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Clinical lung cancer, Vol.18 (6), pp. 595-606.  show abstract

Crabb, S.J. Martin, K. Abab, J. Ratcliffe, I. Thornton, R. Lineton, B. Ellis, M. Moody, R. Stanton, L. Galanopoulou, A. Maishman, T. Geldart, T. Bayne, M. Davies, J. Lamb, C. Popat, S. Joffe, J.K. Nutting, C. Chester, J. Hartley, A. Thomas, G. Ottensmeier, C. Huddart, R. King, E. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European journal of cancer (oxford, england : 1990), Vol.87, pp. 75-83.  show abstract

Pender, A. Rana, S. Delgado, E.I. Proszek, P. Garcia-Murillas, I. Bhosle, J. O'Brien, M. Palma, J.F. Turner, N.C. Popat, S. Downward, J. Gonzalez, D. (2016). 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung cancer, Vol.91, pp. S2-S2.

Puglisi, M. Stewart, A. Thavasu, P. Frow, M. Carreira, S. Minchom, A. Punwani, R. Bhosle, J. Popat, S. Ratoff, J. de Bono, J. Yap, T.A. O''Brien, M. Banerji, U. (2016). Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, Vol.90 (5), pp. 280-288.  show abstract

Kumar, R. Lu, S.K. Minchom, A. Sharp, A. Davidson, M. Gunapala, R. Yap, T.A. Bhosle, J. Popat, S. O’Brien, M.E. (2016). A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer chemotherapy and pharmacology, Vol.77 (2), pp. 375-383.

Marquez-Medina, D. Martin-Marco, A. Popat, S. (2016). Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer. Clinical and translational oncology, Vol.18 (2), pp. 228-232.

Abdelraouf, F. Smit, E. Hasan, B. Menis, J. Popat, S. van Meerbeeck, J.P. Surmont, V.F. Baas, P. O'Brien, M. (2016). Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061). European journal of cancer, Vol.54, pp. 35-39.

Malottki, K. Popat, S. Deeks, J.J. Riley, R.D. Nicholson, A.G. Billingham, L. (2016). Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer. Lung cancer, Vol.92, pp. 1-7.

Marquez-Medina, D. Popat, S. (2016). Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. Future oncology, Vol.12 (6), pp. 815-825.  show abstract

Schuler, M. Wu, Y.-. Hirsh, V. O’Byrne, K. Yamamoto, N. Mok, T. Popat, S. Sequist, L.V. Massey, D. Zazulina, V. Yang, J.C. (2016). First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of thoracic oncology, Vol.11 (3), pp. 380-390.

Schuler, M. Yang, J.C. Park, K. Kim, J.-. Bennouna, J. Chen, Y.-. Chouaid, C. De Marinis, F. Feng, J.-. Grossi, F. Kim, D.-. Liu, X. Lu, S. Strausz, J. Vinnyk, Y. Wiewrodt, R. Zhou, C. Wang, B. Chand, V.K. Planchard, D. Ignatius Ou, S. Planchard, D. Park, K. Schuler, M. Yang, J. Chand, V. Rohr, K. Bagnes, C. Martin, C.M. Recondo, G. Zarba, J.J. Blajman, C. Richardet, M. McLachlan, S.-. Parente, P. Underhill, C. Crombie, C. Mainwaring, P. Greil, R. Humblet, Y. Bustin, F. Carestia, L. Galdermans, D. Lambrechts, M. Delval, L. Vercauter, P. Zhou, C. Wang, J. Huang, C. Lin, X. Wu, Y. Liu, X. Cheng, Y. Qin, S. Feng, J. Huang, J. Zhang, Y. Lu, S. Zereu, M. Garicochea, B. Zadra, C.A. Riska, H. Alanko, T. Cadranel, J. Chouaid, C. Zalcman, G. Sibilot, D.M. Perol, M. Planchard, D. Bennouna, J. Fournel, P. Gervais, R. Rotarski, M. Coudert, B. Schuler, M. Thomas, M. Wehler, T. Faehling, M. Keilholz, U. Laack, E. von Pawel, J. Huber, R. Dickgreber, N. Wiewrodt, R. Mark, Z. Tehenes, S. Strausz, J. Sarosi, V. Prabhash, K. Jain, M. Venkatesan, S. Sharma, L. Dadhich, H. Nagarkar, R.V. Onn, A. Gottfried, M. Stemmer, S. Migliorino, M.R. Grossi, F. Bidoli, P. Bearz, A. Gridelli, C. Milandri, C. Platania, M. Ceresoli, G.L. Cruciani, G. Delgado, F.G. Gonzalez Perez, J.L. Luna, G.A. Baca, O.P. Aerts, J.G. Stigt, J.A. Dingemans, A.M. Herder, G.J. Gans, S.J. Salas Sánchez, J.F. Alvarez Barreda, R.L. Pantigoso, W.R. Palomino, O.L. Jaskiewicz, P. Kazarnowicz, A. Serwatowski, P. Szczesna, A. Jassem, J. Lubennikov, V. Karaseva, N. Orlov, S. Ragulin, Y. Garrido, P. González Larriba, J.L. Camps, C. Campelo, R.G. Lianes, P. Cobo, M. Felip, E. Kim, D.-. Kim, S.-. Park, K. Kim, J.-. Han, J.-. Kim, Y.-. Yang, C.-. Hsia, T.-. Chen, Y.-. Tsai, Y.-. Chang, G.-. Tsao, T.C. Su, W.-. Huang, M.-. Ho, C.-. Hsieh, R.-. Vinnyk, Y. Popovych, O. Ponomarova, O. Bondarenko, I. Polishchuk, I. Shah, R. Mitra, S. Popat, S. Spicer, J. Toy, E. Popat, S. Talbot, T. Brown, E. Upadhyay, S. Summers, Y. Gurtler, J. Meza, L. Thropay, J. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of oncology, Vol.27 (3), pp. 417-423.

Anandappa, G. Popat, S. (2016). Management of lung cancer. Medicine, Vol.44 (4), pp. 244-248.

Weller, A. O'Brien, M.E. Ahmed, M. Popat, S. Bhosle, J. McDonald, F. Yap, T.A. Du, Y. Vlahos, I. deSouza, N.M. (2016). Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. European journal of cancer (oxford, england : 1990), Vol.59, pp. 65-78.  show abstract

Sharp, A. Bhosle, J. Abdelraouf, F. Popat, S. O'Brien, M. Yap, T.A. (2016). Development of molecularly targeted agents and immunotherapies in small cell lung cancer. European journal of cancer (oxford, england : 1990), Vol.60, pp. 26-39.  show abstract

Minchom, A. Punwani, R. Filshie, J. Bhosle, J. Nimako, K. Myerson, J. Gunapala, R. Popat, S. O'Brien, M.E. (2016). A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European journal of cancer, Vol.61, pp. 102-110.

Viola, P. Maurya, M. Croud, J. Gazdova, J. Suleman, N. Lim, E. Newsom-Davis, T. Plowman, N. Rice, A. Montero, M.A. Gonzalez de Castro, D. Popat, S. Nicholson, A.G. (2016). A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of thoracic oncology, Vol.11 (7), pp. 1029-1039.

Pearson, A. Smyth, E. Babina, I.S. Herrera-Abreu, M.T. Tarazona, N. Peckitt, C. Kilgour, E. Smith, N.R. Geh, C. Rooney, C. Cutts, R. Campbell, J. Ning, J. Fenwick, K. Swain, A. Brown, G. Chua, S. Thomas, A. Johnston, S.R. Ajaz, M. Sumpter, K. Gillbanks, A. Watkins, D. Chau, I. Popat, S. Cunningham, D. Turner, N.C. (2016). High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer discovery, Vol.6 (8), pp. 838-851.  show abstract

Marquez-Medina, D. Popat, S. (2016). Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases. Clinical and translational oncology, Vol.18 (8), pp. 760-768.

Novello, S. Barlesi, F. Califano, R. Cufer, T. Ekman, S. Levra, M.G. Kerr, K. Popat, S. Reck, M. Senan, S. Simo, G.V. Vansteenkiste, J. Peters, S. (2016). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.27, pp. v1-v27.

Khalifa, J. Amini, A. Popat, S. Gaspar, L.E. Faivre-Finn, C. (2016). Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of thoracic oncology, Vol.11 (10), pp. 1627-1643.

Pender, A. Garcia-Murillas, I. Rana, S. Cutts, R.J. Kelly, G. Fenwick, K. Kozarewa, I. Gonzalez de Castro, D. Bhosle, J. O'Brien, M. Turner, N.C. Popat, S. Downward, J. (2015). Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. Plos one, Vol.10 (9), pp. e0139074-?.  show abstract

Aitken, K. Popat, S. Nutting, C. McDonald, F. (2015). 76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI). Lung cancer, Vol.87, pp. S30-S30.

Popat, S. Mellemgaard, A. Fahrbach, K. Martin, A. Rizzo, M. Kaiser, R. Griebsch, I. Reck, M. (2015). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future oncology, Vol.11 (3), pp. 409-420.  show abstract

Yang, J.C. Wu, Y.-. Schuler, M. Sebastian, M. Popat, S. Yamamoto, N. Zhou, C. Hu, C.-. O'Byrne, K. Feng, J. Lu, S. Huang, Y. Geater, S.L. Lee, K.Y. Tsai, C.-. Gorbunova, V. Hirsh, V. Bennouna, J. Orlov, S. Mok, T. Boyer, M. Su, W.-. Lee, K.H. Kato, T. Massey, D. Shahidi, M. Zazulina, V. Sequist, L.V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The lancet oncology, Vol.16 (2), pp. 141-151.

Scagliotti, G.V. Bondarenko, I. Blackhall, F. Barlesi, F. Hsia, T.-. Jassem, J. Milanowski, J. Popat, S. Sanchez-Torres, J.M. Novello, S. Benner, R.J. Green, S. Molpus, K. Soria, J.-. Shepherd, F.A. (2015). Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of oncology, Vol.26 (3), pp. 497-504.

Lim, E. Nicholson, A.G. Padley, S. Popat, S. (2015). Never smoker with ground glass opacities on CT. The lancet respiratory medicine, Vol.3 (4), pp. 328-328.

Pender, A. Popat, S. (2015). The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. Therapeutic advances in respiratory disease, Vol.9 (3), pp. 97-104.  show abstract

Hall, P.E. Spicer, J. Popat, S. (2015). Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future oncology, Vol.11 (15), pp. 2175-2191.  show abstract

O’Brien, M.E. Gaafar, R. Hasan, B. Menis, J. Cufer, T. Popat, S. Woll, P.J. Surmont, V. Georgoulias, V. Montes, A. Blackhall, F. Hennig, I. Schmid-Bindert, G. Baas, P. (2015). Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European journal of cancer, Vol.51 (12), pp. 1511-1528.

Soria, J.-. Felip, E. Cobo, M. Lu, S. Syrigos, K. Lee, K.H. Göker, E. Georgoulias, V. Li, W. Isla, D. Guclu, S.Z. Morabito, A. Min, Y.J. Ardizzoni, A. Gadgeel, S.M. Wang, B. Chand, V.K. Goss, G.D. (2015). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. The lancet oncology, Vol.16 (8), pp. 897-907.

Stephens, R.J. Whiting, C. Cowan, K. (2015). Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership. Lung cancer, Vol.89 (2), pp. 175-180.

Middleton, G. Popat, S. Walker, I. Mulatero, C. Spicer, J. Summers, Y. Yap, T.A. Crack, L.R. Billingham, L.J. (2015). The National Lung Matrix Trial: Multi-Drug, Genetic Marker-Directed, Multi-Arm Phase II Trial in Non-Small Cell Lung Cancer. Journal of thoracic oncology, Vol.10 (9), pp. S763-S764.

Billingham, L.J. Brock, K. Crack, L.R. Popat, S. Middleton, G. (2015). Using a Bayesian Adaptive Phase II Trial Design to Test Multiple Genetic-Marker-Directed Drugs in the National Lung Matrix Trial. Journal of thoracic oncology, Vol.10 (9), pp. S372-S372.

Marquez-Medina, D. Popat, S. (2015). Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future oncology, Vol.11 (18), pp. 2525-2540.  show abstract

Gennatas, S. Anbunathan, H. Montero, A. Nicholson, A.G. Popat, S. Bowcock, A.M. (2015). Validation of a Specific Missense GTF2I Mutation in More Indolent Thymic Epithelial Tumours. Journal of thoracic oncology, Vol.10 (9), pp. S403-S403.

Marquez-Medina, D. Popat, S. (2015). Systemic therapy for pulmonary carcinoids. Lung cancer, Vol.90 (2), pp. 139-147.

Cheng, L. Tunariu, N. Collins, D.J. Blackledge, M.D. Riddell, A.M. Leach, M.O. Popat, S. Koh, D.-. (2015). Response evaluation in mesothelioma: Beyond RECIST. Lung cancer, Vol.90 (3), pp. 433-441.

Abdelraouf, F. Sharp, A. Maurya, M. Mair, D. Wotherspoon, A. Leary, A. Gonzalez de Castro, D. Bhosle, J. Nassef, A. Gaafar, T. Popat, S. Yap, T.A. O’Brien, M. (2015). Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. Bmc research notes, Vol.8 (1).

Balachandran, K. Okines, A. Gunapala, R. Morganstein, D. Popat, S. (2015). Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. Bmc cancer, Vol.15 (1).

Middleton, G. Crack, L.R. Popat, S. Swanton, C. Hollingsworth, S.J. Buller, R. Walker, I. Carr, T.H. Wherton, D. Billingham, L.J. (2015). The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of oncology : official journal of the european society for medical oncology, Vol.26 (12), pp. 2464-2469.  show abstract

Gennatas, S. Noble, J. Stanway, S. Gunapala, R. Chowdhury, R. Wotherspoon, A. Benepal, T. Popat, S. (2015). Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres. Bmj open, Vol.5 (1), pp. e006440-e006440.

Marquez-Medina, D. Popat, S. (2015). Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment. Cancer treatment communications, Vol.4, pp. 86-88.

Pender, A. Coward, J. Gunapala, R. Bhosle, J. O'Brien, M. Popat, S. (2014). 38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience. Lung cancer, Vol.83, pp. S15-S15.

Freidin, M.B. Mair, D. Tay, A. Freydina, D.V. Chudasama, D. Popat, S. Nicholson, A.G. Rice, A. Montero-Fernandez, A. Anikin, V. de Castro, D.G. Lim, E. (2014). 8 The utility of peripheral blood circulating tumour cells for the detection of KRAS, EGFR and BRAF mutations in primary lung cancer. Lung cancer, Vol.83, pp. S3-S4.

Popat, S. (2014). Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. Annals of palliative medicine, Vol.3 (1), pp. 19-21.  show abstract

Twelves, C. Chmielowska, E. Havel, L. Popat, S. Swieboda-Sadlej, A. Sawrycki, P. Bycott, P. Ingrosso, A. Kim, S. Williams, J.A. Chen, C. Olszanski, A.J. de Besi, P. Schiller, J.H. (2014). Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of oncology, Vol.25 (1), pp. 132-138.

Abdelraouf, F. de Castro, D.G. Wotherspoon, A. Maurya, M. Mair, D. Bhosle, J. Popat, S. O'Brien, M. (2014). INVESTIGATING MOLECULAR BIOMARKERS IN SCLC. Journal of thoracic oncology, Vol.9 (4), pp. S30-S30.

McDonald, F. Popat, S. (2014). Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. Journal of thoracic disease, Vol.6 (4), pp. 356-368.

Le Quesne, J. Maurya, M. Yancheva, S.G. O’Brien, M. Popat, S. Wotherspoon, A.C. de Castro, D.G. Nicholson, A.G. (2014). A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of thoracic oncology, Vol.9 (6), pp. 769-774.

Pender, A. Popat, S. (2014). Understanding lung cancer molecular subtypes. Clinical practice, Vol.11 (4), pp. 441-453.

Patton, S. Normanno, N. Blackhall, F. Murray, S. Kerr, K.M. Dietel, M. Filipits, M. Benlloch, S. Popat, S. Stahel, R. Thunnissen, E. (2014). Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British journal of cancer, Vol.111 (2), pp. 413-420.

Khan, F. Ottensmeier, C. Popat, S. Dua, D. Dorey, N. Ellis, S. Szabo, M. Upadhyay, S. Califano, R. Chan, S. Lee, L. Ali, C.W. Nicolson, M. Bates, A.T. Button, M. Chaudhuri, A. Mulvenna, P. Shaw, H.M. Danson, S.J. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European journal of cancer, Vol.50 (10), pp. 1717-1721.

Puglisi, M. Thavasu, P. Stewart, A. de Bono, J.S. O’Brien, M.E. Popat, S. Bhosle, J. Banerji, U. (2014). AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung cancer, Vol.85 (2), pp. 141-146.

Popat, S. Mok, T. Yang, J.C. Wu, Y.-. Lungershausen, J. Stammberger, U. Griebsch, I. Fonseca, T. Paz-Ares, L. (2014). Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis. Lung cancer, Vol.85 (2), pp. 230-238.

O'Brien, M.E. Gaafar, R. Hasan, B. Menis, J. Cufer, T. Popat, S. Woll, P. Surmont, V. Georgoulias, V. Montes, A. Blackhall, F. Hennig, I. Schmid-Bindert, G. Baas, P. (2014). Double Blind Randomized Phase III Study of Maintenance Pazopanib® (Pz) Versus Placebo (P) in Non Small Cell Lung Cancer (Nsclc) Patients (Pts) Non Progressive After First Line Chemotherapy [Ct] (Eortc Lung Cancer Group, 08092): Mapping. Annals of oncology, Vol.25, pp. iv435-iv435.

Freydin, M. Freydina, D.V. Chudasama, D. Leung, M. Popat, S. Gonzalez-De-Castro, D. Rice, A. Fernandez, A.M. Nicholson, A.G. Lim, E. (2014). A Blood Based Egfr Mutation Analysis in Circulating Plasma Dna for Prediction of Primary Tumour Mutations in Lung Cancer. Annals of oncology, Vol.25, pp. iv68-iv68.

Reck, M. Popat, S. Reinmuth, N. De Ruysscher, D. Kerr, K.M. Peters, S. (2014). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.25, pp. iii27-iii39.

Gann, C.-. Reck, M. Leighl, N. Nowak, A. Pavlakis, N. Popat, S. Sorensen, J.B. Mueller, M. Von Wangenheim, U. Scagliotti, G. (2014). NINTEDANIB PLUS PEMETREXED/CISPLATIN FOLLOWED BY MAINTENANCE NINTEDANIB FOR UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-AN INTERNATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY. Journal of thoracic oncology, Vol.9 (9), pp. S172-S172.

Rossi, A. Chiodini, P. Sun, J.-. O'Brien, M.E. von Plessen, C. Barata, F. Park, K. Popat, S. Bergman, B. Parente, B. Gallo, C. Gridelli, C. Perrone, F. Di Maio, M. (2014). Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. The lancet oncology, Vol.15 (11), pp. 1254-1262.

Popat, S. Lungershausen, J. Griebsch, I. Marten, A. Wu, Y.L. (2014). Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type. Value in health, Vol.17 (7), pp. A615-A615.

Minchom, A.R. Saksornchai, K. Bhosle, J. Gunapala, R. Puglisi, M. Lu, S.K. Nimako, K. Coward, J. Yu, K.C. Bordi, P. Popat, S. O'Brien, M.E. (2014). An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. Bmj open respiratory research, Vol.1 (1), pp. e000061-e000061.

Linch, M. Gennatas, S. Kazikin, S. Iqbal, J. Gunapala, R. Priest, K. Severn, J. Norton, A. Ayite, B. Bhosle, J. O’Brien, M. Popat, S. (2014). A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. Bmc cancer, Vol.14 (1).

Pender, A. Coward, J. Gunapala, R. Bhosle, J. O'Brien, M. Popat, S. (2013). 33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC). Lung cancer, Vol.79, pp. S12-S12.

NIMAKO, K. GUNAPALA, R. POPAT, S. O'BRIEN, M.E. (2013). Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK. European journal of cancer care, Vol.22 (1), pp. 79-87.

Khan, F. Ottensmeier, C. Popat, S. Danson, S.J. (2013). 30 Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience. Lung cancer, Vol.79, pp. S10-S11.

Freidin, M.B. Tay, A. Chudasama, D. Nicholson, A.G. Rice, A. Bamsey, O. Higgins, A. Popat, S. Anikin, V. Lim, E. (2013). 15 Non-invasive KRAS and EGFR mutation testing of primary lung cancer via peripheral blood circulating tumour cells. Lung cancer, Vol.79, pp. S5-S6.

Weickhardt, A.J. Doebele, R.C. Purcell, W.T. Bunn, P.A. Oton, A.B. Rothman, M.S. Wierman, M.E. Mok, T. Popat, S. Bauman, J. Nieva, J. Novello, S. Ou, S.-. Camidge, D.R. (2013). Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, Vol.119 (13), pp. 2383-2390.

Popat, S. Wotherspoon, A. Nutting, C.M. Gonzalez, D. Nicholson, A.G. O’Brien, M. (2013). Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung cancer, Vol.80 (1), pp. 1-4.

Nimako, K. Lu, S.-. Ayite, B. Priest, K. Winkley, A. Gunapala, R. Popat, S. O'Brien, M.E. (2013). A Pilot Study of a Novel Home Telemonitoring System for Oncology Patients Receiving Chemotherapy. Journal of telemedicine and telecare, Vol.19 (3), pp. 148-152.  show abstract

Alrifai, D. Popat, S. Ahmed, M. Gonzalez, D. Nicholson, A.G. Parcq, J.D. Benepal, T. (2013). A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung cancer, Vol.80 (3), pp. 339-340.

Lim, E. Popat, S. (2013). What exactly are we doing to improve low lung cancer survival in the United Kingdom?. Thorax, Vol.68 (6), pp. 504-505.

Papa, S. Popat, S. Shah, R. Prevost, A.T. Lal, R. McLennan, B. Cane, P. Lang-Lazdunski, L. Viney, Z. Dunn, J.T. Barrington, S. Landau, D. Spicer, J. (2013). Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of thoracic oncology, Vol.8 (6), pp. 783-787.

O’Brien, M.E. Gaafar, R.M. Popat, S. Grossi, F. Price, A. Talbot, D.C. Cufer, T. Ottensmeier, C. Danson, S. Pallis, A. Hasan, B. Van Meerbeeck, J.P. Baas, P. (2013). Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European journal of cancer, Vol.49 (13), pp. 2815-2822.

Balachandran, K. Popat, S. (2013). Endocrine manifestations of malignancy. Medicine, Vol.41 (10), pp. 570-572.

Früh, M. De Ruysscher, D. Popat, S. Crinò, L. Peters, S. Felip, E. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.24, pp. vi99-vi105.

Yap, T.A. Popat, S. (2013). The role of afatinib in the management of non-small cell lung carcinoma. Expert opinion on drug metabolism & toxicology, Vol.9 (11), pp. 1529-1539.

Pender, A. Coward, J. Gunapala, R. Brien, M.O. Bhosle, J. Popat, S. (2013). OUTCOMES OF PATIENTS UNDERGOING ADJUVANT PLATINUM- VINORELBINE CHEMOTHERAPY FOR RESECTED NON- SMALL CELL LUNG CANCER (NSCLC). Journal of thoracic oncology, Vol.8, pp. S1168-S1168.

Le Quesne, J. Maurya, M. De Castro, D.G. Popat, S. Wotherspoon, A. Nicholson, A. (2013). A COMPARISON OF FISH AND IMMUNOHISTOCHEMISTRY IN THE DETECTION OF ALK REARRANGEMENT IN LUNG ADENOCARCINOMA. Journal of thoracic oncology, Vol.8, pp. S1085-S1086.

Freydina, D.V. Tay, A. Chudasama, D. Freidin, M.B. Nicholson, A.G. Rice, A. Montero-Fernandez, A. Popat, S. Anikin, V. Lim, E. (2013). DIAGNOSTIC PERFORMANCE OF A FILTER-BASED ANTIBODY-INDEPENDENT PERIPHERAL BLOOD CIRCULATING TUMOUR CELL CAPTURE PAIRED WITH CYTOMORPHOLOGIC CRITERIA FOR THE DIAGNOSIS OF LUNG CANCER. Journal of thoracic oncology, Vol.8, pp. S1278-S1278.

Lim, E. De Castro, D.G. Popat, S. Shaw, E. Walker, I. Johnson, P. Bamsey, O. Higgins, A. Osadolor, T. Renouf, L. Nicholson, A.G. (2013). FREQUENCY IN EGFR, K-RAS, BRAF AND ALK MUTATIONS IN A COHORT OF CANCERS: ALK TRANSLOCATIONS ARE MORE FREQUENTLY SEEN IN ADVANCED DISEASE. Journal of thoracic oncology, Vol.8, pp. S1222-S1223.

de Mello, R.A. Madureira, P. Carvalho, L.S. Araújo, A. O’Brien, M. Popat, S. (2013). EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, Vol.14 (14), pp. 1765-1777.  show abstract

Gennatas, S. Stanway, S.J. Thomas, R. Min, T. Shah, R. O’Brien, M.E. Popat, S. (2013). Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. Bmc cancer, Vol.13 (1).

Pender, A. Letsa, I. Reid, A. Waddell, T. Nimako, K. Tan, D. Xynos, I. Ayite, B. Priest, K. Watson, S. Stewart, Z. Severn, J. Popat, S. O'Brien, M. (2012). 21 Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients. Lung cancer, Vol.75, pp. S7-S7.

Myerson, J. O'Brien, M. Waddell, T. Reid, A. Gunapala, R. Starling, N. Seet, J.E. Nimako, K. Popat, S. (2012). 76 The UK ‘two week rule’ for lung cancer – 5-year survival update. Lung cancer, Vol.75, pp. S25-S26.

Tai, F.W. Khor, K.S. Popat, S. Beckles, M. Leung, M. Lim, E. (2012). 36 Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. Lung cancer, Vol.75, pp. S12-S12.

Leary, A.F. Castro, D.G. Nicholson, A.G. Ashley, S. Wotherspoon, A. O’Brien, M.E. Popat, S. (2012). Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors. European journal of cancer, Vol.48 (1), pp. 61-67.

Freidin, M. Nicholson, A. Popat, S. Moffatt, M. Cookson, W. Lim, E. (2012). 6 Distribution profile of baseline gene expression to standardise tumour expression: a pilot study of cisplatin resistant genes in lung cancer. Lung cancer, Vol.75, pp. S2-S3.

Coward, J.I. Nathavitharana, R. Popat, S. (2012). True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. Lung cancer, Vol.75 (1), pp. 133-135.

O’Brien, M.E. Myerson, J.S. Coward, J.I. Puglisi, M. Trani, L. Wotherspoon, A. Sharma, B. Cook, G. Ashley, S. Gunapala, R. Chua, S. Popat, S. (2012). A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks. European journal of cancer, Vol.48 (1), pp. 68-74.

Popat, S. Gonzalez, D. Min, T. Swansbury, J. Dainton, M. Croud, J.G. Rice, A.J. Nicholson, A.G. (2012). ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung cancer, Vol.75 (3), pp. 300-305.

Nimako, K. Popat, S. (2012). Management of lung cancer. Medicine, Vol.40 (4), pp. 202-207.

Coward, J.I. Ding, N.-. Feakins, R. Kocher, H. Popat, S. Szlosarek, P.W. (2012). Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. Medical oncology, Vol.29 (4), pp. 2623-2625.

O'Connor, S.J. Elliott, S. Chinegwundoh, J. Popat, S. Rhode, A.L. (2011). 67 Retrospective audit of a district general hospital (DGH) lung multi-disciplinary team (MDT) - lessons from misses and near-misses of treatment deadline. Lung cancer, Vol.71, pp. S23-S23.

Okera, M. Chan, S. Dernede, U. Larkin, J. Popat, S. Gilbert, D. Jones, L. Osuji, N. Sykes, H. Oakley, C. Pickering, L. Lofts, F. Chowdhury, S. (2011). A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network Interpretation of study results in light of NCAG/NCEPOD findings. British journal of cancer, Vol.104 (3), pp. 407-412.

Popat, S. Gonzalez, D. Min, T. Swansbury, J. Dainton, M. Croud, J. Rice, A. Nicholson, A.G. (2011). ALK TRANSLOCATION IS ASSOCIATED WITH ALK IMMUNOREACTIVITY AND EXTENSIVE SIGNET-RING MORPHOLOGY IN PRIMARY LUNG ADENOCARCINOMA. Journal of thoracic oncology, Vol.6 (6), pp. S506-S507.

Leary, A. Gonzalez, D. Nicholson, A.G. Wotherspoon, A. Olansunkanmi, F. O'Brien, M. Popat, S. (2011). SAMPLE QUALITY CRITERIA FOR ROUTINE EGFR MUTATION SCREENING - PATHOLOGICAL FEATURES MAY BE MORE USEFUL THAN CLINICAL PHENOTYPE IN A UK POPULATION. Journal of thoracic oncology, Vol.6 (6), pp. S569-S570.

Pattenden, H. Deshmukh, M. Dusmet, M. Goldstraw, P. Lim, E. Jordan, S. Ladas, G. Popat, S. Rice, A. Von der Thusen, J. Nicholson, A.G. (2011). PERIPHERAL VERSUS CENTRAL RESECTED PRIMARY SQUAMOUS CELL CARCINOMAS OF THE LUNG - A REVIEW OF 526 CASES. Journal of thoracic oncology, Vol.6 (6), pp. S445-S446.

Waddell, T.S. Myerson, J. Reid, A. Ashley, S. Starling, N. Seet, J.-. Nimako, K. Popat, S. O'Brien, M.E. (2011). THE UK TWO WEEK RULE INITIATIVE IN LUNG CANCER - FIRST REPORT OF IMPACT ON DISEASE STAGE AND 5-YEAR SURVIVAL. Journal of thoracic oncology, Vol.6 (6), pp. S523-S524.

Popat, S. Riley, R.D. Billingham, L.J. Hubner, R.A. (2011). EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 (ERCC1) STATUS AND NON-SMALL CELL LUNG CANCER (NSCLC) OUTCOMES: A META-ANALYSIS OF PUBLISHED STUDIES AND RECOMMENDATIONS. Journal of thoracic oncology, Vol.6 (6), pp. S438-S439.

Myerson, J.S. Nimako, K. Moore, S. Karpathakis, A. Calderone, R. Popat, S. O'Brien, M. (2011). QUALITY OF LIFE ASSESSMENTS IN LUNG CANCER AND MESOTHELIOMA A COMPARISON OF QUESTIONNAIRES AND PHYSICIAN CONSULTATION - A POOR WORKMAN ALWAYS BLAMES HIS TOOLS?. Journal of thoracic oncology, Vol.6 (6), pp. S1206-S1207.

Tai, F.W. Khor, K.S. Popat, S. Beckles, M. Leung, M. Al-Sahaf, M. Lim, E. (2011). ONCOLOGISTS, PHYSICIANS AND SURGEONS OPINIONS ON THE PERCEIVED VALUE AND APPROPRIATENESS OF THE SPECIALITY TO INFORM PATIENTS ON ADJUVANT CHEMOTHERAPY AFTER RADICAL SURGERY FOR NON-SMALL CELL LUNG CANCER. Journal of thoracic oncology, Vol.6 (6), pp. S1334-S1334.

Myerson, J.S. Nimako, K. Ranu, H. Madden, B. Popat, S. O'Brien, M. (2011). RANDOMISED EVALUATION OF STENTS TO OPEN RESTRICTED AIRWAYS IN PATIENTS WITH CENTRALLY PLACED NON-SMALL CELL LUNG CANCER (RESTORE - AIR). Journal of thoracic oncology, Vol.6 (6), pp. S1201-S1202.

Reid, A. Waddell, T.S. Nimako, K. Tan, D. Xynos, I. Popat, S. O'Brien, M.E. (2011). WEEKLY PACLITAXEL APPEARS ACTIVE AND WELL-TOLERATED IN THIRD AND FOURTH-LINE ADVANCED NSCLC PATIENTS. Journal of thoracic oncology, Vol.6 (6), pp. S1301-S1301.

Freidin, M.B. Bhudia, N. Lim, E. Nicholson, A.G. Popat, S. Cookson, W.O. Moffatt, M.F. (2011). SAMPLE HANDLING AND PROCESSING ARE CRITICAL FACTORS INFLUENCING THE RESULTS OF WHOLE GENOME GENE EXPRESSION PROFILING IN LUNG CANCER TISSUES. Journal of thoracic oncology, Vol.6 (6), pp. S373-S374.

Patton, S. Thunnissen, E. Murray, S. Benlloch, S. Butler, R. Dietel, M. Filipits, M. Kerr, K.M. Normanno, N. Popat, S. Wallace, A. Stahel, R. Taron, M. Blackhall, F. (2011). A PILOT EXTERNAL QUALITY ASSURANCE SCHEME FOR SOMATIC EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER. Journal of thoracic oncology, Vol.6 (6), pp. S1510-S1511.

Calderone, R. Nimako, K. Leary, A. Popat, S. O’Brien, M.E. (2011). Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication. European journal of cancer, Vol.47 (11), pp. 1603-1605.

Hubner, R.A. Goldstein, R. Mitchell, S. Jones, A. Ashley, S. O’Brien, M.E. Popat, S. (2011). Influence of co-morbidity on renal function assessment by Cockcroft–Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung cancer, Vol.73 (3), pp. 356-360.

Popat, S. Vieira de Araújo, A. Min, T. Swansbury, J. Dainton, M. Wotherspoon, A. Lim, E. Nicholson, A.G. O'Brien, M.E. (2011). Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib. Journal of thoracic oncology, Vol.6 (11), pp. 1962-1963.

Dong-bing, Z. Chandler, I. Zheng-ming, C. Hong-chao, P. Popat, S. Yong-fu, S. Houlston, R.S. (2011). Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor beta receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis. Chinese medical journal, Vol.124 (4), pp. 483-490.

Khor, K.S. Tai, D. Popat, S. Beckles, M. Leung, M. Al Sahaf, M. Lim, E.K. (2011). Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. J clin oncol, Vol.29 (15_suppl), p. 7011.  show abstract

Khor, K.S. Tai, D. Popat, S. Beckles, M. Leung, M. Al Sahaf, M. Lim, E.K. (2011). Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. Journal of clinical oncology, Vol.29 (15_suppl), pp. 7011-7011.

Goldstein, R. Reid, F. Campbell, J. Popat, S. Benepal, T. (2010). Neurosurgery for brain metastases (BM) in the management of non-small cell lung cancer (NSCLC): A retrospective study of all cerebral metastasectomies at St George's Hospital London (SGH), 1999–2009. Lung cancer, Vol.67, pp. S38-S38.

Hubner, R. Goldstein, R. Mitchell, S. Jones, A. Ashley, S. O'Brien, M. Popat, S. (2010). Influence of co-morbidity on renal function estimation by Cockcroft Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung cancer, Vol.67, pp. S9-S9.

Lim, E. Baldwin, D. Beckles, M. Duffy, J. Entwisle, J. Faivre-Finn, C. Kerr, K. Macfie, A. McGuigan, J. Padley, S. Popat, S. Screaton, N. Snee, M. Waller, D. Warburton, C. Win, T. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, Vol.65 (Suppl 3), pp. iii1-iii27.

Forster, M. Enting, D. Nicholson, A.G. O’Brien, M. Popat, S. (2010). The combination of Young's syndrome and small cell lung cancer—A spiky connection?. Lung cancer, Vol.67 (3), pp. 372-375.

Nicholson, A.G. Gonzalez, D. Shah, P. Pynegar, M.J. Deshmukh, M. Rice, A. Popat, S. (2010). Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. Journal of thoracic oncology, Vol.5 (4), pp. 436-441.

Calderone, R.G. Nimako, K. Leary, A.N. Popat, S. Kipps, E. O'Brien, M.N. (2010). USE OF ZOLEDRONIC ACID IN LUNG CANCER. Journal of thoracic oncology, Vol.5 (5), pp. S99-S100.

Brunetto, A.T. Carden, C.P. Myerson, J. Faria, A.L. Ashley, S. Popat, S. O'Brien, M.E. (2010). Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of thoracic oncology, Vol.5 (9), pp. 1397-1403.

Myerson, J.S. Iqbal, S.A. O’Brien, M.E. Popat, S. (2010). Supersensitive Mutation: Two Case Reports of Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical lung cancer, Vol.11 (5), pp. E5-E8.

Myerson, J.S. Faria, A. Puglisi, M. Starling, N. Popat, S. O’Brien, M.E. (2010). The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer. Lung cancer, Vol.69 (3), pp. 365-366.

Trani, L. Myerson, J. Ashley, S. Young, K. Sheri, A. Hubner, R. Puglisi, M. Popat, S. O’Brien, M.E. (2010). Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung cancer, Vol.70 (2), pp. 200-204.

Puglisi, M. Dolly, S. Faria, A. Myerson, J.S. Popat, S. O'Brien, M.E. (2010). Treatment options for small cell lung cancer – do we have more choice?. British journal of cancer, Vol.102 (4), pp. 629-638.

Irshad, S. Popat, S. Shah, R.N. Burbridge, S. Lal, R. Lang-Lazdunski, L. Viney, Z. Marsden, P. Barrington, S. Spicer, J.F. (2010). A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET. Journal of clinical oncology, Vol.28 (15_suppl), pp. 7038-7038.

Benson, C. Kristeleit, R.S. Ashley, S. Dolly, S. Mikropoulos, C. O'Brien, M. Popat, S. (2010). Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital. Journal of clinical oncology, Vol.28 (15_suppl), pp. 7095-7095.

Myerson, J.S. Moore, S.A. Popat, S. O'Brien, M.E. (2010). Quality of Life Assessments in Lung Cancer - An evaluation of three questionnaires What's best for routine clinical practice?. American journal of respiratory and critical care medicine, Vol.181.

Benning, J. Starling, N. Myerson, J.S. Popat, S. Ashley, S. O'Brien, M.E. (2009). An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy – urgent need for specific SCLC guidelines. Lung cancer, Vol.63, pp. S13-S13.

Faria, A. Myerson, J.S. Puglisi, M. Starling, N. Ashley, S. Popat, S. O'Brien, M.E. Bruzynski, P. (2009). The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients. Lung cancer, Vol.63, pp. S4-S4.

Baird, R. Mikropoulos, C. Ashley, S. Killick, E. Myerson, J.S. Wotherspoon, A. O'Brien, M.E. Popat, S. Jackson-Jones, R. (2009). Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC). Lung cancer, Vol.63, pp. S2-S3.

Dolly, S.O. Popat, S. (2009). Endocrine manifestations of malignancy. Medicine, Vol.37 (9), pp. 457-460.

O'Brien, M.E. Myerson, J.S. Popat, S. Puglisi, M. Starling, N. Trani, L. Bhupinder, S. Gary, C. Sue, A. (2009). The use of PET-CT scan in the assessment of response to Tarceva (erlotinib) in non small cell lung (NSCLC) cancer patients. Journal of thoracic oncology, Vol.4 (9), pp. S390-S391.

Popat, S. Barbachano, Y. Ashley, S. Norton, A. O’Brien, M. (2008). Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung cancer, Vol.59 (2), pp. 227-231.

Hughes, S. Barbachano, Y. Ashley, S. Yap, Y.-. Popat, S. Allen, M. Della-Rovere, U.Q. Johnston, S. Smith, I. O’Brien, M. (2008). Time Trends in the Outcome of Elderly Patients with Breast Cancer. The breast journal, Vol.14 (2), pp. 158-163.

O'Brien, M.E. Yau, T. Coward, J. Hughes, S. Papadopoulos, P. Popat, S. Norton, A. Ashley, S. (2008). Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age≥70 Years) with Non-small Cell Lung Cancer. Clinical oncology, Vol.20 (2), pp. 142-147.

Brunetto, A. Carden, C.P. Ashley, S. Baird, R. Myerson, J. Kristeleit, R. Montes, A. Popat, S. O'Brien, M. (2008). Dose intensity in advanced non-small cell lung cancer. Lung cancer, Vol.60, pp. S20-S20.

Ho, G.F. Popat, S. Nutting, C. (2008). Induction and concurrent chemoradiotherapy for non-small cell lung cancer (NSCLC) using cisplatin and vinorelbine. Lung cancer, Vol.60, pp. S18-S18.

Carden, C.P. Myerson, J.S. Popat, S. Montes, A. Larkin, J.M. Benson, M.J. O'Brien, M.E. (2008). Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports. Journal of thoracic oncology, Vol.3 (5), pp. 539-541.

Popat, S. Smith, I.E. (2008). Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature clinical practice oncology, Vol.5 (6), pp. 324-335.

Sirohi, B. Arnedos, M. Popat, S. Ashley, S. Nerurkar, A. Walsh, G. Johnston, S. Smith, I.E. (2008). Platinum-based chemotherapy in triple-negative breast cancer. Annals of oncology, Vol.19 (11), pp. 1847-1852.

Drilon, A.D. Popat, S. Bhuchar, G. D'Adamo, D.R. Keohan, M.L. Fisher, C. Antonescu, C.R. Singer, S. Brennan, M.F. Judson, I. Maki, R.G. (2008). Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer, Vol.113 (12), pp. 3364-3371.  show abstract

Sirohi, B. Arnedos, M. Popat, S. Ashley, S. Nerurkar, A. Walsh, G. Johnston, S. Smith, I.E. (2008). Platinum-based chemotherapy in triple-negative (TN) breast cancer. Journal of clinical oncology, Vol.26 (15_suppl), pp. 1051-1051.

Dernedde, U. Chan, S. Sykes, H. Oakley, C. Larkin, J. Popat, S. Gilbert, D. Jones, L. Chowdhury, S. (2008). South West London Cancer Network (SWLCN) audit of patients with chemotherapy-induced febrile neutropenia (CIFN). Journal of clinical oncology, Vol.26 (15_suppl), pp. 20653-20653.

Tjellström, B. Stenhammar, L. Högberg, L. Fälth-Magnusson, K. Magnusson, K.-. Midtvedt, T. Sundqvist, T. Houlston, R. Popat, S. Norin, E. (2007). Gut microflora associated characteristics in first-degree relatives of children with celiac disease. Scandinavian journal of gastroenterology, Vol.42 (10), pp. 1204-1208.

Popat, S. Zhao, D.B. Chen, Z.M. Pan, H.C. Sha, Y.F. Chandler, I. Houlston, R.S. (2007). Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients (vol 27, pg 627, 2007). Anticancer research, Vol.27 (2), pp. 1231-1.

Popat, S. Hughes, S. Papadopoulos, P. Wilkins, A. Moore, S. Priest, K. Meehan, L. Norton, A. O’Brien, M. (2007). Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung cancer, Vol.56 (1), pp. 135-137.

Sirohi, B. Ashley, S. Norton, A. Popat, S. Hughes, S. Papadopoulos, P. Priest, K. O'Brien, M. (2007). Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival. Journal of thoracic oncology, Vol.2 (8), pp. 735-740.

Wilkins, A. Popat, S. Hughes, S. O’Brien, M. (2007). Malignant pleural mesothelioma: Two cases in first degree relatives. Lung cancer, Vol.57 (3), pp. 407-409.

Popat, S. Zhao, D. Chen, Z. Pan, H. Shao, Y. Chandler, I. Houlston, R.S. (2007). Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer research, Vol.27 (1B), pp. 627-633.

Hubner, R.A. Muir, K.R. Liu, J.-. Logan, R.F. Grainge, M. Armitage, N. Shepherd, V. Popat, S. Houlston, R.S. (2006). Genetic Variants of UGT1A6 Influence Risk of Colorectal Adenoma Recurrence. Clinical cancer research, Vol.12 (21), pp. 6585-6589.  show abstract

Yau, T. Ashley, S. Popat, S. Norton, A. Matakidou, A. Coward, J. O'Brien, M.E. (2006). Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer. British journal of cancer, Vol.94 (1), pp. 18-21.

Popat, S. Smith, I.E. (2006). Breast cancer. Update on cancer therapeutics, Vol.1 (2), pp. 187-210.

Popat, S. Lopez, J. Chan, S. Waters, J. Rutter, D. E Hill, M. (2006). Palliative treatments for patients with inoperable gastroesophageal cancers. International journal of palliative nursing, Vol.12 (7), pp. 306-317.  show abstract

Popat, S. Chen, Z. Zhao, D. Pan, H. Hearle, N. Chandler, I. Shao, Y. Aherne, W. Houlston, R.S. (2006). A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Annals of oncology, Vol.17 (12), pp. 1810-1817.

Popat, S. Wort, R. Houlston, R.S. (2006). Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. Bmc cancer, Vol.6 (1).  show abstract

Johnson, V. (2005). Exon 3  -catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut, Vol.54 (2), pp. 264-267.

Popat, S. Smith, I.E. (2005). Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. Jnci: journal of the national cancer institute, Vol.97 (11), pp. 858-858.

Popat, S. Wort, R. Houlston, R.S. (2005). Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers. International journal of surgical pathology, Vol.13 (2), pp. 127-133.  show abstract

Popat, S. O??Brien, M. (2005). Chemotherapy strategies in the treatment of small cell lung cancer. Anti-cancer drugs, Vol.16 (4), pp. 361-372.

Popat, S. Houlston, R.S. (2005). A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. European journal of cancer, Vol.41 (14), pp. 2060-2070.

Rini, B.I. Small, E.J. (2005). Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma. Journal of clinical oncology, Vol.23 (5), pp. 1028-1043.  show abstract

Popat, S. Matakidou, A. Houlston, R.S. (2005). In Reply:. Journal of clinical oncology, Vol.23 (9), pp. 2108-2109.

Popat, S. Houlston, R.S. (2005). Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Jnci: journal of the national cancer institute, Vol.97 (24), pp. 1855-1855.

POPAT, S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J clin oncol, Vol.23, pp. 609-618.

Popat, S. Matakidou, A. Houlston, R.S. (2004). Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis. Journal of clinical oncology, Vol.22 (3), pp. 529-536.  show abstract

Sumpter, K. Harper-Wynne, C. Yeoh, C. Popat, S. Ashley, S. Norton, A. O’Brien, M. (2004). Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?. Lung cancer, Vol.43 (3), pp. 369-370.

Popat, S. Nicholson, A.G. Fisher, C. Harmer, C. Moskovic, E. Murday, V.A. Houlston, R.S. (2004). Pulmonary Masses Presenting 11 Years after Abdominal Surgery. Respiration, Vol.71 (3), pp. 295-297.

Hodgson, S.V. Popat, S. (2003). Polymorphic sequence variants in medicine: a challenge and an opportunity. Clinical medicine, Vol.3 (3), pp. 260-264.

Popat, S. Stone, J. Houlston, R.S. (2003). Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. Cancer genetics and cytogenetics, Vol.145 (1), pp. 70-73.

Popat, S. (2002). Genome screening of coeliac disease. Journal of medical genetics, Vol.39 (5), pp. 328-331.

Popat, S. Hearle, N. Wixey, J. Hogberg, L. Bevan, S. Lim, W. Stenhammar, L. Houlston, R.S. (2002). Analysis of the CTLA4 Gene in Swedish Coeliac Disease Patients. Scandinavian journal of gastroenterology, Vol.37 (1), pp. 28-31.

Popat, S. Hearle, N. Bevan, S. Hogberg, L. Stenhammar, L. Houlston, R.S. (2002). Mutational Analysis of CD28 in Coeliac Disease. Scandinavian journal of gastroenterology, Vol.37 (5), pp. 536-539.

Popat, S. Hearle, N. Hogberg, L. Braegger, C.P. O'Donoghue, D. Falth-Magnusson, K. Holmes, G.K. Howdle, P.D. Jenkins, H. Johnston, S. Kennedy, N.P. Kumar, P.J. Logan, R.F. Marsh, M.N. Mulder, C.J. Torinsson Naluai, A. Sjoberg, K. Stenhammar, L. Walters, J.R. Jewell, D.P. Houlston, R.S. (2002). Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Annals of human genetics, Vol.66 (Pt 2), pp. 125-137.  show abstract

Popat, S. Hearle, N. Bevan, S. Holmes, G.K. Howdle, P.D. Hogberg, L. Braegger, C.P. O'Donoghue, D. Falth-Magnusson, K. Jenkins, H. Johnston, S. Kennedy, N.P. Kumar, P. Logan, R.F. Marsh, M.N. Mulder, C.J. Sjoberg, K. Stenhammar, L. Walters, J.R. Jewell, D.P. Houlston, R.S. (2002). A genetic analysis of coeliac disease. Gut, Vol.50, pp. A92-A92.

Popat, S. Hogberg, L. McGuire, S. Green, H. Bevan, S. Stenhammar, L. Houlston, R.S. (2001). Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population. European journal of gastroenterology & hepatology, Vol.13 (12), pp. 1477-1479.

Popat, S. Stone, J. Coleman, G. Marshall, G. Peto, J. Frayling, I. Houlston, R. (2000). Prevalence of the APC E1317Q variant in colorectal cancer patients. Cancer letters, Vol.149 (1-2), pp. 203-206.

Bevan, S. Popat, S. Houlston, R.S. (1999). Relative power of linkage and transmission disequilibrium test strategies to detect non-HLA linked coeliac disease susceptibility genes. Gut, Vol.45 (5), pp. 668-671.

Bevan, S. Catovsky, D. Marossy, A. Matutes, E. Popat, S. Antonovic, P. Bell, A. Berrebi, A. Gaminara, E.J. Quabeck, K. Ribeiro, I. Mauro, F.R. Stark, P. Sykes, H. van Dongen, J. Wimperis, J. Wright, S. Yuille, M.R. Houlston, R.S. (1999). Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia, Vol.13 (10), pp. 1497-1500.

Bevan, S. Popat, S. Braegger, C.P. Busch, A. O'Donoghue, D. Falth-Magnusson, K. Ferguson, A. Godkin, A. Hogberg, L. Holmes, G. Hosie, K.B. Howdle, P.D. Jenkins, H. Jewell, D. Johnston, S. Kennedy, N.P. Kerr, G. Kumar, P. Logan, R.F. Love, A.H. Marsh, M. Mulder, C.J. Sjoberg, K. Stenhammer, L. Walker-Smith, J. Marossy, A.M. Houlston, R.S. (1999). Contribution of the MHC region to the familial risk of coeliac disease. Journal of medical genetics, Vol.36 (9), pp. 687-690.

Brown, S.A. Popat, S. Carr, R. (1997). An unusual cause of chest pain. Postgraduate medical journal, Vol.73 (866), pp. 825-827.

Matakidou, A. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis, Vol.25 (3), pp. 369-373.

Popat, S. Yap, T. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmacogenomics and personalized medicine, , pp. 285-285.

True. Leukemia, Vol.13 (10), pp. 1497-1500.

Minchom, A. Mak, D. Gunapala, R. Walder, D. Kumar, R. Yousaf, N. Hodgkiss, A. Bhosle, J. Popat, S. O'Brien, M.E. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. Plos one, Vol.14 (11), pp. e0225509-?.  show abstract

Hubner, R.A. Riley, R.D. Billingham, L.J. Popat, S. Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. Plos one, Vol.6 (10), pp. e25164-e25164.

Garcia Campelo, M.R. Lin, H.M. Zhu, Y. Pérol, M. Jahanzeb, M. Popat, S. Zhang, P. Camidge, D.R. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L). Lung cancer (amsterdam, netherlands), Vol.155, pp. 68-77.  show abstract

Popat, S. Brustugun, O.T. Cadranel, J. Felip, E. Garassino, M.C. Griesinger, F. Helland, Å. Hochmair, M. Pérol, M. Bent-Ennakhil, N. Kruhl, C. Novello, S. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung cancer (amsterdam, netherlands), Vol.157, pp. 9-16.  show abstract

Tomasik, B. Bieńkowski, M. Braun, M. Popat, S. Dziadziuszko, R. Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis. Lung cancer (amsterdam, netherlands), Vol.158, pp. 97-106.  show abstract

Popat, S. Liu, G. Lu, S. Song, G. Ma, X. Yang, J.C. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future oncology (london, england), Vol.17 (32), pp. 4237-4247.  show abstract

Begum, P. Goldin, R.D. Possamai, L.A. Popat, S. Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report. Jto clinical and research reports, Vol.2 (9), pp. 100213-?.  show abstract

Hindocha, S. Campbell, D. Ahmed, M. Giorgakoudi, K. Sharma, B. Yousaf, N. Molyneaux, P. Hunter, B. Kalsi, H. Cui, W. Davidson, M. Bhosle, J. Minchom, A. Locke, I. McDonald, F. O'Brien, M. Popat, S. Lee, R.W. Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in medicine, Vol.8, pp. 764563-?.  show abstract

Curcean, S. Cheng, L. Picchia, S. Tunariu, N. Collins, D. Blackledge, M. Popat, S. O'Brien, M. Minchom, A. Leach, M.O. Koh, D.-. Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. Jto clinical and research reports, Vol.2 (12), pp. 100253-?.  show abstract

Popat, S. Hsia, T.-. Hung, J.-. Jung, H.A. Shih, J.-. Park, C.K. Lee, S.H. Okamoto, T. Ahn, H.K. Lee, Y.C. Sato, Y. Lee, S.S. Mascaux, C. Daoud, H. Märten, A. Miura, S. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). The oncologist, Vol.27 (4), pp. 255-265.  show abstract

Yang, J.C. Schuler, M. Popat, S. Miura, S. Park, K. Passaro, A. De Marinis, F. Solca, F. Märten, A. Kim, E.S. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. Frontiers in oncology, Vol.12.  show abstract

Popat, S. Liu, S.V. Scheuer, N. Gupta, A. Hsu, G.G. Ramagopalan, S.V. Griesinger, F. Subbiah, V. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer. Jama network open, Vol.5 (5), pp. e2214046-e2214046.

Aguilar‐Duran, S. Mee, J. Popat, S. Heelan, K. Atezolizumab‐induced linear IgA bullous dermatosis. British journal of dermatology, .


Book Chapters

Popat, S. Treatment of Cancer. Nutrition and Cancer. (pp. 27-44). John Wiley & Sons, Ltd..


Conferences

Zhang, Y.Z.Brambilla, C.Molyneaux, P.L.Rice, A.Robertus, J.L.Jordan, S.Lim, E.Lang-Lazdunski, L.Begum, S.Dusmet, M.Anikin, V.Popat, S.Cookson, W.O.Moffatt, M.F.Nicholson, A.G. (2020). Atypical mesothelial proliferation (amp) of the pleura: multidisciplinary approach, prognostic stratification and proposal of minimally invasive malignant pleural mesothelioma, VIRCHOWS ARCHIV, Vol.477, pp.S24-2.

Kordbacheh, T.Kumar, R.Biondo, A.Tan, R.Yap, T.Popat, S.Bhosle, J.O'Brien, M.E. (2016). 47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden, Lung Cancer, Vol.91, p.S17.

Dumas, L.Macklin-Doherty, A.Wu, X.O'Brien, M.E.Popat, S.Yap, T.Bhosle, J. (2016). 72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer, Lung Cancer, Vol.91, p.S26.

Bainbridge, H.Toms, C.Kilburn, L.Popat, S.Bliss, J.Mcdonald, F. (2016). 141 HALT trial: stereotactic radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours – results of a national trial feasibility questionnaire, Lung Cancer, Vol.91, p.S51.

Smyth, E.C.Turner, N.C.Pearson, A.Peckitt, C.Chau, I.Watkins, D.J.Starling, N.Rao, S.Gillbanks, A.Kilgour, E.Sumpter, K.A.Smith, N.R.Cutts, R.Rooney, C.Thomas, A.L.Ajaz, M.A.Chua, S.Brown, G.Popat, S.Cunningham, D. (2016). Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results., Journal of Clinical Oncology, Vol.34 (4_suppl), p.154.

Minchom, A.R.Punwani, R.Filshie, J.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.O'Brien, M.E. (2016). 163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma, Lung Cancer, Vol.91, p.S59.

Leung, M.Freidina, D.Nicholson, A.Rice, A.Freidin, M.Fernandez, A.M.Popat, S.Lim, E. (2016). 1 A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour, Lung Cancer, Vol.91, p.S1.

Viola, P.Popat, S.Khan, O.Moule, R.Polychronis, A.Stokoe, J.Dickson, J.Montero Fernandez, A.Amat Villegas, I.Yancheva, S.Gonzalez de Castro, D.Nicholson, A.G. (2015). 83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment, Lung Cancer, Vol.87, pp.S32-S33.

Pender, A.Garcia-Murillas, I.Rana, S.de Castro, D.G.Turner, N.Popat, S.Downward, J. (2015). Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Clinical Research (Excluding Clinical Trials), .

Brock, K.Billingham, L.Crack, L.Popat, S.Middleton, G. (2015). 186: Forecasting patient recruitment for time-to-event analysis in National Lung Matrix Trial, Lung Cancer, Vol.87, p.S69.

Middleton, G.Billingham, L.Crack, L.Popat, S.Walker, I. (2015). 187: National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer, Lung Cancer, Vol.87, pp.S69-S70.

Papadatos-Pastos, D.Roda, D.Luken, M.D.Jalil, A.Diamantis, N.Michalarea, V.Lima, J.Capelan, M.Bodla, S.Bhosle, J.Molife, R.O'Brien, M.Banerji, U.Popat, S.Yap, T. (2015). 339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH), European Journal of Cancer, Vol.51, p.S67.

Papadatos-Pastos, D.Roda, D.Luken, M.J.Michalarea, V.Lima, J.Diamantis, N.Capelan, M.Jalil, A.Bodla, S.Bhosle, J.Molife, R.O'Brien, M.Banerji, U.Popat, S.Yap, T.A. (2015). Clinical Outcome and Prognostic Factors for Advanced Malignant Mesothelioma (MM) Patients (pts) Treated on Phase I Trials, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S504-S505.

Kumar, R.Lo, K.Minchom, A.R.Sharp, A.Davidson, M.Gunapala, R.Yap, T.Bhosle, J.Popat, S.O'Brien, M.E. (2015). A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S547-S548.

Viola, P.Devaraj, A.Lim, E.Luciano, G.Popat, S.Nicholson, A.G. (2015). Pathology-Imaging Agreement in Distinguishing Separate Primary Tumours and Intrapulmonary Metastasis in Staging of Multiple Lung Cancers, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S261-S262.

Viola, P.Maurya, M.Croud, J.Gazdova, J.Suleman, N.Lim, E.Popat, S.Rice, A.Fernandez, A.M.De Castro, D.G.Nicholson, A.G. (2015). A Validation Study for the Use of ROS-1 Immunohistochemistry in Screening for ROS-1 Translocations in Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S694.

Lu, S.K.Anbunathan, H.Popat, S.O'Brien, M.E.Lim, E.Fernandez, A.M.Nicholson, A.G.Lathrop, M.Bowcock, A.M.Moffatt, M.F.Cookson, W.O. (2015). Molecular Landscape of Malignant Mesothelioma from Whole Exome Sequencing, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S253.

O'Brien, M.E.Minchom, A.R.Punwani, R.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.Filshie, J. (2015). Randomised Study of Acupuncture, Morphine and Combination in NSCLC/Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S366-S367.

Popat, S.Felip, E.Cobo, M.Fulop, A.Dayen, C.Trigo, J.M.Gregg, R.Waller, C.F.Gordon, J.Lorence, R.Wang, B.Chand, V.K.Hirsh, V. (2015). 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial, European Journal of Cancer, Vol.51, pp.S626-S627.

Yang, J.C.Popat, S.Bazhenova, L.Blakely, C.M.Dichman, R.Felip, E.Griesinger, F.Groen, H.J.Gurubhagavatula, S.Leach, J.W.Novello, S.Perol, M.Patel, R.Reckamp, K.Georgiou, P.Miyamoto, E.Isaacson, J.Wakelee, H.A. (2015). TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S430.

Leung, M.Freidin, M.Freidina, D.Popat, S.Nicholson, A.Rice, A.Fernandez, A.M.Lim, E. (2015). A Comparative Analysis of Cancer Hotspot Mutation Profiles in Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary Lung Tumour, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S604.

Besse, B.Menis, J.Adam, J.Berghmans, T.Cufer, T.Dziadziuszko, R.Felip, E.Finn, S.P.Lacroix, L.Mazieres, J.Melgaard, P.Novello, S.Peters, S.Popat, S.Reck, M.Smit, E.Vansteenkiste, J.Hasan, B.Steuve, J.Varin, E.Lacombe, D.Stahel, R. (2015). SPECTAlung: Screening Patients with Thoracic Tumors for Efficient Clinical Trial Access, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S706-S707.

Stahel, R.A.Dafni, U.Gautschi, O.Felip, E.Curioni-Fontecedro, A.Peters, S.Massutí, B.Cardenal, F.Aix, S.P.Früh, M.Pless, M.Popat, S.Kotsakis, A.Cuffe, S.Bidoli, P.Favaretto, A.Carcereny, E.Sanchez Ronco, M.Molina, M.A.Rosell, R. (2015). 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial, European Journal of Cancer, Vol.51, pp.S711-S712.

Smyth, E.C.Turner, N.Pearson, A.Peckitt, C.Chau, I.Watkins, D.Kilgour, E.Smith, N.R.Gillbanks, A.Chua, S.Brown, G.Cutts, R.Rooney, C.Llavero, N.T.Thomas, A.Popat, S.Cunningham, D. (2015). Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results, ANNALS OF ONCOLOGY, Vol.26, p.44.

Smyth, E.C.Turner, N.C.Peckitt, C.Pearson, A.Brown, G.Chua, S.Gillbanks, A.Johnston, S.R.TARAZONA, N.Cutts, R.Kilgour, E.Rooney, C.Smith, N.R.Sumpter, K.A.Ajaz, M.A.Thomas, A.L.Watkins, D.Chau, I.Popat, S.Cunningham, D. (2015). Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours., Journal of Clinical Oncology, Vol.33 (15_suppl), p.2508.

Yang, J.C.Popat, S.Georgiou, P.Miyamoto, E.Isaacson, J.D.Wakelee, H.A. (2015). TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Gadgeel, S.M.Dols, M.C.Felip, E.Soria, J.-.Lee, K.H.Lu, S.Georgoulias, V.Fulop, A.Goker, E.Syrigos, K.N.Morabito, A.Coskun, H.S.Guclu, S.Z.Li, W.Popat, S.Ardizzoni, A.Lungershausen, J.Wang, B.Chand, V.K.Goss, G.D.Investigators, L.-. (2015). Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Pender, A.Garcia-Murillas, I.de Castro, D.G.Popat, S.Downward, J. (2014). 13 Molecular profiling of non-small cell lung cancer (NSCLC) – the liquid biopsy comes of age, Lung Cancer, Vol.83, p.S5.

Fennell, D.Antonov, A.Martins, M.L.Popat, S.Ramalingam, S.S.Spicer, J.Vukovic, V.M.El-Hariry, I.Reichert, V.Rosell, R. (2014). Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC, Presented at Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Clinical Research (Excluding Clinical Trials), .

Freydina, D.V.Tay, A.Chudasama, D.Freidin, M.B.Nicholson, A.G.Rice, A.Montero-Fernandez, A.Popat, S.Anikin, V.Lim, E. (2014). 47 The ability of a filter-based antibody-independent approach to capture circulating tumour cells for the diagnosis of lung cancer, Lung Cancer, Vol.83, pp.S17-S18.

Capelan, M.Roda, D.Geuna, E.Rihawi, K.Shankar, B.Kaye, S.B.Bhosle, J.Molife, L.R.Banerji, U.Óbrien, M.De Bono, J.S.Popat, S.Yap, T.A. (2014). Clinical Outcome of Advanced Non-Small Cell Lung Cancer Patients (Ansclc Pts) on Phase I Trials in the Drug Development Unit (Ddu) at the Royal Marsden Hospital (Rmh), Annals of Oncology, Vol.25, p.iv434.

Rimner, A.Litvak, A.M.Detterbeck, F.C.Filosso, P.L.Bruce, P.Ahmad, U.Rajan, A.Popat, S.Huang, J.Riely, G.J. (2014). A SURVEY OF CURRENT CLINICAL MANAGEMENT OF THYMIC CARCINOMAS AMONG ITMIG PHYSICIANS, JOURNAL OF THORACIC ONCOLOGY, Vol.9 (10), pp.S235-S236.

Sequist, L.Wu, Y.Schuler, M.O'Byrne, K.Sebastian, M.Popat, S.Boyer, M.Mok, T.Yamamoto, N.Hirsh, V.Geater, S.L.Zhou, C.Massey, D.Zazulina, V.Jones, H.Yang, J. (2014). Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6), International Journal of Radiation Oncology*Biology*Physics, Vol.90 (5), pp.S5-S6.

Scagliotti, G.V.Leighl, N.B.Nowak, A.K.Pavlakis, N.Popat, S.Sorensen, J.B.Barrueco, J.Kaiser, R.Loembe, A.-.Mueller, M.von Wangenheim, U.Reck, M. (2014). Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS7612.

Lim, E.K.Freidin, M.B.Freydina, D.V.Chudasama, D.Leung, M.Popat, S.Gonzalez de Castro, D.Rice, A.Anikin, V.Montero Fernandez, A.Nicholson, A.G. (2014). A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer., Journal of Clinical Oncology, Vol.32 (15_suppl), p.7563.

Lu, S.Popat, S.Puglisi, M.Kaudeer, N.Gennatas, S.Hewish, M.Ayite, B.Bhosle, J.O'Brien, M. (2013). Phase 1b study of capecitabine and erlotinib in advanced non-small cell lung cancer, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S828.

Freidin, M.B.Mair, D.Tay, A.Freydina, D.V.Chudasama, D.Popat, S.Nicholson, A.G.Rice, A.Montero-Fernandez, A.Anikin, V.De Castro, D.G.Lim, E. (2013). THE EFFICIENCY OF DETECTION OF KRAS, EGFR AND BRAF MUTATIONS IN PRIMARY LUNG CANCER VIA PERIPHERAL BLOOD CIRCULATING TUMOUR CELLS, JOURNAL OF THORACIC ONCOLOGY, Vol.8, p.S456.

Puglisi, M.Thavasu, P.Stewart, A.Bhosle, J.Popat, S.O'Brien, M.E.Banerji, U. (2013). Abstract 2441: Evaluation of combination of an EGFR and AKT inhibitor inEGFRmutant andEGFRwild type non-small cell lung cancer cells lines., Presented at Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC, Clinical Research, .

Smyth, E.C.Turner, N.C.Popat, S.Morgan, S.Owen, K.Gillbanks, A.Jain, V.K.Cunningham, D. (2013). FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Papa, S.Popat, S.Shah, R.McLennan, B.Lal, R.Lang-Lazdunski, L.Marsden, P.Viney, Z.Landau, D.Spicer, J. (2012). A PHASE 2 STUDY OF SORAFENIB AFTER FIRST LINE PLATINUM CONTAINING COMBINATION CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA, JOURNAL OF THORACIC ONCOLOGY, Vol.7 (6), p.S84.

Popat, S. (2012). LARGE CELL NEUROENDOCRINE CARCINOMA: HOW SHOULD IT BE TREATED?, JOURNAL OF THORACIC ONCOLOGY, Vol.7 (6), p.S18.

Twelves, C.Chmielowska, E.Havel, L.Popat, S.Swieboda-Sadlej, A.Sawrycki, P.Bycott, P.Niethammer, A.De Besi, P.Schiller, J.H. (2012). RANDOMISED PHASE II STUDY OF AXITINIB OR BEVACIZUMAB COMBINED WITH PACLITAXEL/CARBOPLATIN (PAC/CARB) AS FIRST-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), ANNALS OF ONCOLOGY, Vol.23, p.409.

O'Brien, M.Gaafar, R.M.Popat, S.Grossi, F.Price, A.Talbot, D.C.Cufer, T.Ottensmeier, C.H.Danson, S.Pallis, A.G.Hasan, B.Van Meerbeeck, J.P.Baas, P. (2012). Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Trani, L.Myerson, J.Young, K.Sheri, A.Hubner, R.Puglisi, M.Popat, S.O'Brien, M.E. (2009). 9054 Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations, European Journal of Cancer Supplements, Vol.7 (2), p.521.

Faria, A.Myerson, J.S.Puglisi, M.Starling, N.Ashley, S.Popat, S.O'Brien, M.E. (2009). 9062 The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients, European Journal of Cancer Supplements, Vol.7 (2), pp.523-524.

Rigual, N.R.Cheney, R.T.Iwenofu, O.H.Li, Q.Loree, T.R.Popat, S.R.Merzianu, M. (2007). Idiosyncrasies of Scalp Melanoma, The Laryngoscope, Vol.117 (8), pp.1354-1358.

Popat, S.Zhao, D.B.Chen, Z.M.Pan, H.C.Sha, Y.F.Chandler, I.Houlston, R.S. (2007). Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients (vol 27, pg 627, 2007), ANTICANCER RESEARCH, Vol.27 (2), p.1231.

Chandler, I.P.Popat, S.Pan, H.Zhao, D.Shao, Y.Chen, Z.Houlston, R.S. (2006). A prospective study confirms mismatch repair status predicts outcome in colorectal cancer, JOURNAL OF PATHOLOGY, Vol.210, p.7.

Popat, S.Pan, H.Shao, Y.Zhao, D.Chen, Z.Houlston, R.S. (2005). A prospective blinded study of microsatellite instability (MSI) as a marker of overall survival (OS) in the adjuvant treatment of colorectal cancer (CRC) patients., JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.847S.

Sirohi, B.Matakidou, A.Ashley, S.Popat, S.Saka, W.Priest, K.Norton, A.James, M.Benepal, T.Eisen, T.O'Brien, M. (2005). Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival., JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.672S.

Yau, T.Ashley, S.Popat, S.Norton, A.Matakidou, A.Priest, K.James, M.O'Brien, M.E. (2005). Case-control study comparing the cisplatin-based chemotherapy toxicity between elderly (age >/=70) and younger patient with lung cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.680S.

Yau, T.Ashley, S.Popat, S.Norton, A.Matakidou, A.O'Brien, M. (2005). P-596 Chemotherapy treatments outcome and toxicities in the treatmentof elderly patients (age ⩾ 70) with lung cancer, Lung Cancer, Vol.49, p.S275.

Sirohi, B.Matakidou, A.Benson, C.Ashley, S.Priest, K.Norton, A.James, M.Saka, W.Popat, S.O'Brien, M. (2005). PD-082 Early response to platinum-based chemotherapy in nonsmall cell lung cancer (NSCLC) predicts survival unluike in mesotheliomas, Lung Cancer, Vol.49, p.S91.

Popat, S.Hubner, R.Houlston, R.S. (2004). A meta-analysis of microsatellite instability and colorectal cancer prognosis., JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.853S.

Andreopoulou, E.Ross, P.J.O'Brien, M.E.Norton, A.Priest, K.Ashley, S.Popat, S.Harper-Wynne, C.Sumpter, K.Smith, I.E. (2003). The use of MVP chemotherapy in malignant mesothelioma: Outcome and predictive factors, BRITISH JOURNAL OF CANCER, Vol.88, p.S22.

In this section

Publications